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 1 
SUMMARY 
 
The genetic alterations associated with acute leukemia can be divided into two 
functional groups. The class I mutations enhance cellular proliferation and survival by 
constitutive activation of mainly protein tyrosine kinases signaling pathways. In 
contrast, the class II mutations frequently involve transcriptional regulators of normal 
hematopoietic differentiation, and result in a block of hematopoietic cell maturation 
and/or aberrant self-renewal capacity. However, expression of the class II mutations 
in the murine hematopoietic system often leads to myelodysplasic changes and 
acute leukemia after a long latency, suggesting that collaboration of additional 
genetic alterations might be required. 
 
To identify potential cooperating genetic events facilitating induction of acute 
leukemia by the class II mutations, we modeled acute myelogenous leukemia (AML) 
in mouse by retrovirally expressing the MLL/ENL and MOZ/TIF2 fusion genes in the 
bone marrow. The genetic background of leukemic mice (F1 hybrid mice resulting 
from crossbreeding the FVB/N and 129/s1 strains) allowed us to perform a genome-
wide polymorphism analysis screening for loss of heterozygosity (LOH) that is 
frequently found in blasts from AML patients. However, a simple sequence length 
polymorphism (SSLP) based allelotyping as well as a mouse 5K single nucleotide 
polymorphism (SNP) array analysis did not showed any LOH, indicating that large 
scale of LOH might be a rare event in our mouse leukemia models.  
 
Recent studies have shown that genomic insertion of retrovirus could influence the 
expression of adjacent genes and therefore contribute to oncogenic transformation of 
hematopoietic cells. The retroviral integration tagging approach has been widely 
used for seeking new proto-oncogenes or tumor suppressor genes, and especially 
for identifying collaborative events in tumor models that already harbored an initiating 
oncogenic event. To test the hypothesis that the integration of the provirus could act 
as cooperating events in our mouse leukemia models, we characterized the retroviral 
integration sites from 21 leukemic mice induced by retroviral expression of MLL/ENL 
and MOZ/TIF2 fusion genes. Sixty-six integration flanking genes were identified, and 
most of them have been previously linked to tumorigenesis. Further determination of 
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their expression levels demonstrated that integration flanking genes like Tcf7, Tnfrsf1, 
Mn1 and Lhx2 were up-regulated, whereas Pur?, Ppp2r5c, Runx3, Socs1 and Prdm2 
were down-regulated. Interestingly, in a MLL/ENL leukemic mouse carrying the 
integration adjacent to the meningioma 1 (Mn1) gene, the clone harboring the Mn1 
integration prevailed over other co-existing clones harboring different integrations. 
Moreover, an in vitro cellular proliferation assay showed that the overexpression of 
MN1 significantly enhanced proliferation and self-renewal capacity of primary bone 
marrow cells. These findings suggested that MN1 possesses leukemic transforming 
potential and might functionally collaborate with the MLL/ENL fusion in the 
development of the acute leukemia. 
  
In order to experimentally address this hypothesis, we performed a series of bone 
marrow transplant experiments. Indeed, co-expression of MN1 with MLL/ENL 
enhanced in vivo disease development, and resulted in a significantly reduced 
latency for induction of an aggressive acute leukemia than expression of MN1 or 
MLL/ENL alone. In addition, co-expression of MN1 increased the granulocyte-
macrophage progenitor (GMP) cell population expressing Gr1/Mac1, Cd34 and c-Kit 
with leukemia-initiating properties as shown in secondary transplantation 
experiments. As MN1 has been previously proposed to exert its function as a 
transcriptional co-activator, we also aimed to identify the potential downstream target 
genes by transient MN1 expression in primary bone marrow cells. Gene expression 
profiling experiments revealed a series of genes with known roles in normal or 
malignant hematopoiesis such as CD34, FLT3, HLF, and DLK1 that were 
upregulated in MN1 overexpressing murine leukemias, as well as pediatric acute 
leukemias with high MN1 levels.  
 
We also determined the MN1 levels in a large panel of pediatric acute leukemias. 
High MN1 expression levels were observed in 50 of 87 samples: high MN1 levels 
were found in a large proportion of B-cell ALL cases and in most infant leukemias 
that carry MLL fusions and are of B-cell origin. Additionally, siRNA-mediated MN1 
knockdown resulted in cell cycle arrest and impaired clonogenic growth of human 
leukemia cell lines with high MN1 levels but not in cells with low (or undetectable) 
MN1 levels, suggesting the aberrant expression of MN1 contributes to malignant 
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cellular proliferation, and the inhibition of MN1 could represent a new therapeutic 
approach. 
 
Taken together, while searching for cooperative genetic alterations in murine 
leukemias, we found that elevated levels of MN1 oncogene can act as a functional 
collaborator in MLL/ENL (and probably other class II mutations) induced leukemia 
through a distinct genetic program that increases the leukemia stem cell pool. In 
addition, we also demonstrated for the first time that high MN1 levels are found in a 
significant fraction of childhood acute leukemias, and important for proliferation of the 
leukemic cells.  
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INTRODUCTION 
 
1. Leukemia is a malignant disease in the blood system 
 
Leukemia is defined as cancer of the blood forming system and characterized by 
abnormal proliferation of leukocytes (white blood cells). The disease is grouped into 
different clinical and pathological entities. Acute leukemia is characterized by a rapid 
increase of immature blood cells that do not perform the normal function, whereas in 
chronic leukemia, abnormal blood cells are excessively produced, although they are 
terminally differentiated and can still execute their normal function. Depending on 
which lineage is affected, leukemia is subdivided into myeloid leukemia involving the 
granulocytic, monocytic, erythroid or megakaryocytic cell lineage, or lymphocytic 
leukemia involving the B-cell, T-cell or natural killer (NK)-cell lineage. Based on these 
classifications, four main leukemia categories are defined, namely acute 
myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute 
lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). ALL occurs 
most commonly in children and is the most common type of leukemia in young 
children, whereas CLL most often affects adults over the age of 55. AML and CML 
both also occur more frequently in adults than in children 1. 
 
The standard treatment regimen for most forms of leukemia includes chemotherapy 
with combination of different anti-cancer drugs depending on the leukemia subtype. 
Allogeneic or autologous bone marrow transplantation in combination with 
polychemotherapy can lead to cure for some patients, however, a large proportion of 
adult patients with acute leukemia face relapse and ultimately die from their disease. 
Intensive research efforts are ongoing to identify new compounds that are able to 
selectively target the leukemic cells. The small molecule protein kinase inhibitors 
such as imatinib (Gleevec®) is successfully used to treat patients of chronic phase 
CML with a five-year overall survival rate of 90% 2.  In AML, initial remissions can be 
achieved in over 70% of patients with conventional chemotherapy, however the five-
year survival rate is below 40% and most patients relapse within 5 years despite 
continued treatment 3. To develop more effective targeted therapeutics, the better 
understanding of molecular basis of the disease is necessary.   
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2. Leukemia as stem cell disease  
 
In the hematopoietic system, stem cells and lineage marker negative progenitors 
account for less than 0.01-0.05% of the cells in bone marrow, and are divided into 
three different populations according to their ability to self-renew. Long-term 
hematopoietic stem cells (LT-HSCs) give rise to short-term HSCs, which in turn give 
rise to more restricted progenitors. During this process, the cells gradually lose their 
self-renewing potential and become mitotically more active. LT-HSCs have an 
indefinite propagation potential, and generate all lineages of mature cells through 
consecutive differentiation. In contrast, there is basically no detectable self-renewal 
potential in restricted progenitors, which can only give rise to single or oligo-lineages 
of hematopoietic cells 4. 
 
Biological studies on acute myeloid leukemia (AML) have demonstrated that only 
0.1% to 1% of the AML cells have the capacity to initiate the disease when injected 
into severe combined immunodeficient (SCID) mice 5,6. These findings suggested 
that similar to normal hematopoiesis, leukemia is also a mixture of cells with different 
phenotypic characteristics as well as proliferative and self-renewal potentials. A small 
number of stem cells can restore themselves and maintain the disease, whereas the 
majority of leukemia cells are in a more "mature" state, unable to initiate the disease. 
In other words, “leukemic stem cells” (LSCs) seem to undergo an aberrant and poorly 
regulated process of hematopoiesis that is somehow analogous to the self-renewal 
and differentiation of normal stem cells 7.  
 
The first experimental evidence suggesting the existence of LSCs came from 
observations made almost 40 years ago: only 1 out of 10,000-100’000 mouse 
myeloma cells obtained from mouse ascites were able to form colonies in semi-solid 
medium 8. Similarly, human leukemia cells from AML patients also formed colonies at 
very low frequency suggesting the presence of a small number of self-renewing cells 
within the bulk of leukemic blasts 9,10. 
 
The gold standard for identifying leukemic stem cells is initiating the disease by 
xenotransplantation of human leukemic blasts in severe immunodeficient recipients, 
usually non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. In 
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most human AML subtypes (with the exception of acute promyelocytic leukemia), the 
leukemia stem cells seem to be in the CD34+CD38– or CD34+CD38+/low cell fraction 5. 
Similarly, experiments using a xenograft model of chronic phase of human chronic 
myeloid leukemia demonstrated that LSCs of the chronic-phase CML also resided in 
CD34+CD38– compartment 11.  
 
3. Therapeutic targeting of leukemia stem cells 
 
A high frequency of disease relapse suggests that conventional chemotherapeutic 
regimes only eradicate proliferating leukemic bulk cells, but fail to efficiently target 
leukemia stem cells. Several studies suggested that similar to normal HSCs, the 
majority of LSCs remain silent in G0 phase of cell cycle which makes this malignant 
population refractory to standard chemotherapy that generally hits actively dividing 
cells. LSCs also possess another HSC-like property, they also express high levels of 
ATP-associated transporter proteins, which contribute to multidrug resistance and 
survival from chemotherapy 12 13.  
  
Currently, the rising research efforts were exerted on developing therapeutic 
strategies to selectively impairing the proliferation, survival or self-renewal of the 
LSCs while protecting normal HSCs. Such strategies could work through knockdown 
of genes that are essential regulators of leukemia stem cells self-renewing, although 
unfortunately, most genes contributing to LSCs function seem also to play important 
roles in their normal counterparts. Additionally, the surface makers predominantly 
expressed on LSCs could also help to selectively target LSCs 7.  
 
There is increasing knowledge about the signaling pathways that are involved in 
proliferation and self-renewal of LSCs. It has been shown that aberrant NF-kappaB 
and PI3K signaling might control survival and maintenance of LSCs 14,15. NF-kappaB 
is a transcription factor normally activated by inflammatory stimuli and during 
lymphoid development. Recent experiments showed that normal human CD34+ 
progenitor cells do not express NF-kappaB, but NF-kappaB activity was found in 
AML stem cells. A novel functional NF-kappa B inhibitor (through blocking the 
upstream activator IKK) parthenolide induced selective apoptosis in AML stem cells 
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associated with p53 activation and increased reactive oxygen species (ROS) 
production. These studies demonstrated a paradigm that aberrant expression of NF-
kappaB in LSCs could provide a unique therapeutic target for LSCs 14,16.  
  
The lipid kinase phosphoinositide 3-kinase (PI3K)-AKT/PKB-mammalian target of 
rapamycin (mTOR) signaling pathway may present another therapeutic target for 
LSCs. PI3K activity was necessary for the survival of human AML blasts and 
treatment with pharmacologic inhibitors of PI3K or mTOR, combined with standard 
induction chemotherapy, induced apoptosis in AML cells and decreased the 
abundance of LSCs 15,17. The phosphatase and tensin homologue (PTEN) protein 
functions as a negative regulator of PI3K-AKT/PKB. In a mouse model with 
conditional PTEN deficiency, PTEN ablation in the hematopoietic system initially 
impaired the maintenance of HSCs and led to development of a myeloproliferative 
disease that progressed to acute leukemia within weeks. The treatment with 
rapamycin, an inhibitor of mTOR, substantially blocked the generation or 
maintenance of LSCs and restored normal HSC function. Thus, based on differential 
dependence of PTEN, treatment with rapamycin could preferentially eradicate LSCs, 
and restore normal HSCs on the other hand 18,19. As aberrant PI3K-AKT/PKB 
signaling is able to activate NF-kappaB, combining inhibitors of PI3K or mTOR with 
NF-kappaB inhibitors might have additive effects for elimination of LSCs. Several 
clinical trials are currently ongoing to explore the safety and efficacy of inhibitors of 
PI3K-AKT/PKB and NF-kappa B for the therapy of acute leukemia 20. 
 
One promising approach for eliminating LSCs would be to turn-off critical LSC 
regulatory genes by using the RNA interference technology. By comparing gene 
expression profile of HSCs and committed progenitors with LSCs in a model of 
leukemia induced by retroviral expression of an MLL/AF9 fusion oncogene, a small 
subset of LSC self-renewal associated genes was identified, including the HOXA 
cluster genes and the transcription factor MEF2C. Suppression of MEF2C expression 
by short hairpin shRNA not only reduced the colony-forming activity, but also 
strikingly impaired the development of leukemia in vivo when transplanting into 
secondary recipient mice 21. Once the major obstacle of efficient in vivo delivery of 
interfering RNAs is solved, due to its high specificity this approach might be very 
promising 22. 
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Another potential strategy for selective LSC eradication might be monoclonal 
antibody based therapeutics specifically targeting LSC cell surface antigens. These 
antibodies could be engineered to deliver toxic anti-leukemia drugs, whose effects 
are limited to leukemia stem cells, with less or no effect on healthy cells. Several 
studies have suggested that LSCs exhibited some surface antigens that were 
different from normal HSCs. LSCs isolated from AML patients generally lacked 
expression of Thy-1 (CD90) 23 and c-Kit (CD117) 24 but expressed interleukin (IL)-3 
receptor ? (CD123) on the cell surface 25 and a novel antigen C-type lectin-like 
molecule-1 (CLL-1) was present exclusively on leukemic but not normal 
CD34+CD38? cells 26,27, suggesting they would be rational cell-surface targets. 
Indeed, binding of CD123 with a diptheria toxin–IL-3 fusion protein selectively 
diminished LSCs in vitro and also impaired the AML engraftment of NOD/SCID mice 
25
 
28. Additionally, CD44, an adhesion molecule involved in a variety of cellular activity 
including organogenesis, cell homing and migration, has emerged recently as 
another promising target. Anti-CD44 monoclonal antibodies were able to induce 
differentiation and apoptosis of AML blasts and abolish leukemic repopulation in 
NOD/SCID mice through impairing the homing ability and viability of LSCs. These 
studies indicated that the interaction between LSC and stem cell niches is a 
prerequisite for maintenance of LSCs and provides a convincing direction for 
therapeutic intervention 29 30. LSC-specific antibodies could also be conjugated with 
siRNAs which knock down crucial genes for the survival of leukemia stem cells. More 
interestingly, it has been shown that an antibody based siRNA delivery approach 
might reduce toxicity and increase specificity compared to conjugating with a 
cytotoxic agent 31. 
 
With the advent of new technologies, like next generation sequencing, high-
throughput genetic and epigenetic screening for LSC specific programs, we might be 
soon able to obtain a better understanding of its biology. Further biochemical and 
genetic studies of human patient samples and mouse leukemia models will provide 
essential clues for viable targets of specific therapeutic intervention. Based on it, a 
successful ‘precision bombing’ will be performed to eliminate LSCs and prevent 
relapse of the disease. 
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4. Leukemia as the product of functionally collaborating 
genetic lesions  
 
LSCs share many functional and phenotypic similarities with HSCs, such as self-
renewal potential and the maintenance of a quiescent stage. It has been rationally 
postulated that LSCs arise from HSCs as the result of accumulation of oncogenic 
mutations, based on the observation that stem cells persist for long periods and 
undergo a number of cell divisions increasing the likelihood to obtain the minimum 
number of mutations necessary for malignant transformation 5,6,32. Alternatively, 
LSCs may also result from more differentiated progenitor cells that have reacquired 
the capacity for self-renewal and accumulated additional mutations for malignant 
transformation. 33,34 
 
The intensive molecular investigation over the past two decades has shed new light 
on the pathogenesis of hematological malignancies. A large number of recurrent 
genetic lesions have been identified to be associated with different subtypes of 
leukemias. Conventional cytogenetic analysis initially uncovered the presence of 
chromosomal translocations, large deletions and inversions. Improved molecular 
tools then allowed identification of smaller mutations like point mutation, 
microdeletions that are often associated with normal karyotypes. Several biological 
assays have been developed over the years to examine the in vitro transforming 
potential of leukemia-associated genetic lesions. In addition, in vivo oncogenic 
activity of an increasing number of leukemia-associated mutations has been 
demonstrated in well-designed animal models. Based on their cellular activity, it has 
been proposed to classify leukemia-associated genetic alterations into two functional 
groups. The class I mutations generally consist of genetic lesions that activate signal 
transduction pathways conferring cell survival and proliferation advantage, whereas 
the class II mutations comprise mutations that alter a transcriptional program 
essential for normal hematopoietic differentiation resulting in aberrant self-renewal 
and maturation arrest (Fig. I ) 35,36. 
The class I mutations 
 
The class I mutations increase proliferation and survival potential of hematopoietic 
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stem and progenitor cells, often through constitutive activation of protein tyrosine 
kinases (PTKs) but normally do not affect cellular differentiation. Examples include 
gain-of-function mutations of ABL, JAK2, FLT3, PDGFR, KIT, activating mutation of 
the RAS family members, as well as loss-of-function alterations of NF1 or PTPN11 37. 
Activating JAK2 mutations are found in chronic myeloproliferative neoplasms and in 
more than 95% of patients with polycythemia vera (PV). Activating mutations of FLT3, 
KIT and RAS are present in more than 50% of AML patients. FLT3 is the most 
commonly mutated gene in approximately one third of AML. In 20%–25% of cases of 
AML, internal tandem duplications (ITD) in the juxtamembrane domain of FLT3 
results in loss of an autoinhibitory domain leading to constitutive activation. Other 
FLT3 mutations consist of substitutions, small deletions, or insertions within the 
activation loop of the second kinase domain found in 5% to 10% of AML patients. 
The overall consequence of these FLT3 mutations is ligand-independent receptor 
dimerization and/or constitutive activation of its tyrosine kinase activity, leading to 
uncontrolled activation of several downstream signaling pathways, such as RAS, 
MAPK, and STAT5 pathways. The RAS/MAPK signal transduction pathway is a 
critical regulator of proliferation and survival of hematopoietic progenitors. Leukemic 
blasts from about 40% of AML patients showed constitutive activation of RAS 
signaling 38. However, expression of most class I mutations in murine bone marrow 
generally leads to a lethal myeloproliferative disease (MPD), but not acute leukemia. 
In addition, most of these disorders such as the FLT3-ITD induced MPD are not 
transplantable into secondary recipient mice suggesting that the class I mutations do 
not confer self-renewal potential to the transformed cells 37. 
 
The class II mutations 
 
The class II mutations impair differentiation and augment self-renewal properties of 
hematopoietic progenitors by modulation of chromatin remodeling and recruitment of 
aberrant co-activator or -repressor complexes, while having modest effects on cell 
proliferation or survival. The class II mutations comprise gene rearrangements 
affecting transcriptional regulators such as the core-binding factor CBF, CEBP?, 
RAR?, and MLL, and components of the transcriptional activation complex such as 
CBP, MOZ, and TIF2, which are all critical regulators for the differentiation program 
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of hematopoietic stem and progenitor cells. The core-binding factor (CBF) is a 
heterodimeric transcription factor composed by the AML1 (also known as RUNX1) 
and the CBF? subunits, which are both essential for normal hematopoiesis 39. Thus, 
disruptions of the AML1/CBF? complex might cause differentiation arrest and 
subsequent leukemic transformation. Indeed, CBF is the target of multiple 
chromosomal translocations and mutations. Among them, the most frequent and 
extensively studied are the AML1/ETO (RUNX1/ETO) resulting from t(8;21) and 
CBFB/SMMHC from inv(16), which are present in approximately 10% and 5% of AML 
cases, respectively. The chromosomal rearrangements involving retinoic acid 
receptor alpha (RAR?) on chromosome 15 are exclusively associated with acute 
promyelocytic leukemia (APL). APL-associated gene rearrangements are 
characterized by fusing RAR? to several different partner genes, of which the most 
common fusion is PML/RAR? resulting from t(15;17). PML/RAR? inhibits the function 
of RAR? by a dominant negative effect through recruiting the co-repressor complex, 
in a manner similar to the AML1/ETO, CBFB/SMMHC and ETV6/ AML1 fusions 38. 
The MOZ/TIF2 fusion is generated by chromosomal rearrangement inv(8)(p11q13) 
associated with AML. MOZ (monocytic leukemia zinc finger) is a MYST family histone 
acetyltransferase (HAT), and the C2HC zinc finger nucleosome binding motif of MOZ 
is essential for leukemic transforming potential of the MOZ/TIF2 fusion, whereas HAT 
activity of MOZ is dispensable. TIF2 (transcription intermediary factor-2) belongs to 
the p160 nuclear receptor transcriptional coactivator family (NRCoAs) that interacts 
with CREB binding protein (CBP), which is also critical for transformation activity of 
MOZ/TIF2 40. A large number of studies have demonstrated that retroviral or 
transgenic expression of the class II mutations often led to development of 
myelodysplastic syndrome or AML-like phenotype in the mouse.  However, the 
requirement of a relatively long latency for the onset of the disease suggested that 
the class II mutations might be essential but rather not sufficient for induction of an 
acute leukemia phenotype 38. 
 
The class II mutations also play an important role in aberrant activation of self-
renewal property of LSCs. Retroviral expression of a MLL/ENL fusion gene (a class II 
mutation associated with AML and ALL) in purified HSCs, or well defined (by 
expression  of distinct surface markers)  progenitor cells such as common myeloid 
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progenitors (CMPs) or granulocyte–macrophage progenitors (GMPs) led to 
immortalization in vitro and rapid onset of transplantable AMLs with almost identical 
phenotypes 34. Similarly, CMP and GMP transduced with other class II mutations 
such as the MOZ/TIF2 or MLL/AF9 fusions (but not the class I mutation BCR/ABL) 
also initiated AML in recipient mice, suggesting human AML might also arise from 
committed myeloid progenitors on which self-renewal capacity was conferred by the 
aberrant transcription activity of those fusion genes 21,41. Impressively, the LSCs in 
this set of the class II mutations induced murine leukemias exhibited a GMP-like 
immunophenotype, lacking expression of lineage markers, but highly expressing the 
stem or early progenitor markers such as CD34, c-Kit, and the Fc? receptor II and III 
(CD16/CD32) 21,34,41. The secondary transplantation of limiting dose of flowcytometer-
sorted cells led to the estimation that 0.6–0.8% of the cells in bone marrow or spleen 
are LSCs 21,34,41. However, this concept was recently challenged by the work of 
Cleary M.L. and colleagues who demonstrated that a high percentage of colony-
forming cells (CFCs) from the bone marrow and spleen of leukemic mice can also 
initiate the disease in secondary recipients. These clonogenic cells were more 
frequent, accounting for 25%-30% of leukemic blasts, and expressed more mature 
myeloid lineage-specific markers 42. Further evidence also arose from observations 
made with a transgenic B-cell lymphoma model. In this model, malignant cells 
transferred the disease to non-irradiated histocompatible recipients at a very high 
frequency (at least 1 in 10), supporting an idea that the analysis based on limiting-
dilution transplantation experiments in immunodeficient animals might underestimate 
the actual LSC frequency 43. 
 
The identity of LSCs might be also dependent on the type of the class II mutations as 
shown in a murine model of CALM (clathrin assembly lymphoid myeloid 
leukemia)/AF10 (ALL fused gene from chromosome 10) fusion positive AML. In 
contrast to acute leukemia induced by MLL/AF9 or MOZ/TIF2, the leukemia 
propagating cells had the phenotype of early B-lymphoid progenitors 
(B220+CD11b?Gr-1?) with clonal immunoglobulin heavy-chain gene rearrangements. 
Similar to the murine model, CALM/AF10-positive AML patients also showed a 
population of CD45RA (the human homolog of B220) positive leukemic cells 
displaying clonal Ig DH-JH rearrangements that were able to form CFU-blast colonies 
in vitro 44. Furthermore, the LSCs in PML/RAR?-induced APL seem to more likely 
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reside in CD34–CD38+ than CD34+CD38– compartment (as shown in MLL/AF9 
leukemia) 45. These observations probably reveal a truth that the different origins of 
LSCs and the distinct class II mutations underlying leukemic transformation lead to 
the diversity of LSC phenotype, which would make a universal targeted therapy 
approach for all subtypes of leukemia rather unlikely. 
 
Functional cooperation of the class I and class II mutations in acute 
leukemia 
 
Clinical and experimental data support the idea that acute leukemic blasts harbor 
more than one recurring mutations, strongly suggesting a multi-hit model for 
leukemogenesis. Recent studies have shown that although some class II mutations, 
such as the MLL/AF4 or TEL/AML1 fusion genes arise in utero, the protracted 
postnatal latency for the onset of leukemia is still observed in patients, indicating 
additional secondary genetic alterations were required to develop the leukemic 
phenotype 46,47. A recent study on a monochorionic twin pair, one with frank leukemia 
and one in pre-leukemic stage, further demonstrated that the TEL/AML1 fusion gene 
can act as a first-hit mutation and additional hits would have impact on progression of 
leukemia 48. The genetic analysis of progression from chronic myelogenous leukemia 
(CML) to acute myelogenous leukemia (AML) also provided evidence for multi-step 
pathogenesis of acute leukemia. Several cases were reported as evidence, in which 
progression of chronic myeloproliferative disorders induced by the class I mutations 
such as BCR/ABL or TEL/PDGFR? fusions to AML was associated with the 
acquisition of the class II mutations such as AML1/EVI1, AML1/ETO or 
NUP98/HOXA9 fusion. It strongly suggests that the class I mutations can act in 
concert with the class II mutations to cause AML 35. In a recent comprehensive 
mutational study including 144 de novo diagnosed AML cases, 103 of 165 identified 
mutations were overlapped with other mutations, mostly consisting of the class I and 
class II mutations 49.   
 
Generally, the mutations in the same group rarely occurred in the same AML patient. 
In contrast, the mutations from different complementation groups were frequently 
found in the same patient. In PML/RAR? positive acute promyelocytic leukemia 
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(APL), more than 30% patients also harbor FLT3 activating mutations 37. 
Experimental observations from murine models of APL provided solid evidence for 
functional cooperation between PML/RAR? and activating FLT3 mutations. 
Expression of PML/RAR? from the cathepsin G promoter in transgenic mice resulted 
in APL-like disease with a long latency (more than 6 months) and incomplete 
penetrance (~15%–30%) 37. However, the retroviral expression of FLT3-ITD in bone 
marrow of these PML/RAR? transgenic mice induced APL after a shorter latency and 
complete penetrance, suggesting that FLT3 mutations function as an additional hit 
and accelerator of the disease progression 50. The functional cooperation between 
the class I and class II mutations have also been demonstrated in other mouse 
leukemia models. Expression of the BCR/ABL fusion causes a fatal 
myeloproliferative syndrome, however, co-expression of NUP98/HOXA9 with 
BCR/ABL rapidly induced a fatal AML phenotype that was in concordance with the 
observation of progression of CML chronic phase to blast crisis in patients 51. Two of 
the most frequently gene rearrangements associated with AML, AML1/ETO and 
FLT3 length mutation, are insufficient to cause leukemia in animal models on their 
own. Nevertheless, retroviral expression of both of mutations together efficiently 
induced acute myeloid leukemia in mice, further supporting the concept of oncogenic 
collaboration between complementation mutations in leukemic transformation of 
hematopoietic progenitors 52. Moreover, direct functional collaboration of the 
activating FLT3-ITD mutation with the MLL/AF9 was recently demonstrated in the 
bone marrow transplantation leukemia model 53. Interestingly, the mutation of the p53 
tumor suppressor gene seems to occur in conjunction with both of the class I and 
class II mutations and associated with multi-lineage dysplasia and a complex 
karyotype, indicating p53 mutations might present a functionally distinct class of 
mutation 49. 
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Fig. I. A functional collaboration model of genetic alterations leading to acute leukemia.  
In acute leukemia, genetic alterations are distinguished as the class I and class II mutations. 
The class I mutations usually affect kinases and other signaling proteins, which provide 
proliferative and/or survival advantage and induce a myeloproliferative disease rather than 
frank leukemia in mouse models. The class II mutations that alter transcription activities of 
common transcription factors impair differentiation and could result in a myelodysplastic 
syndrome-like disease or acute leukemia after a long latency in mouse models. Co-
expression of class I with class II mutations in mice rapidly induces an acute leukemia 
phenotype. 
 
5. Mixed lineage leukemia (MLL) gene in acute leukemia 
 
Among the most common genes affected by the leukemogenic class II mutations is 
the MLL (Mixed Lineage Leukemia or Myeloid/Lymphoid Leukemia) gene on 
chromosome 11q23, also known as ALL-1, HTRX or HRX, which is frequently 
involved in chromosomal translocations. These translocations result in novel chimeric 
proteins containing the amino terminus of MLL fused in-fame with over 50 distinct 
partner proteins 54,55. MLL gene rearrangements are observed in about 80 % of infant 
leukemia, 10% of childhood leukemia patients older that 1 year of age, and 
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approximately 5-10% of adult acute leukemias of either lymphoid or myeloid lineage 
derivation. In addition to spontaneously arising leukemia, MLL fusions are also found 
in patients with therapy-related leukemias occurring after treatment with inhibitors of 
topoisomerase II, which account for 5-10% of MLL associated leukemias. Generally, 
chromosomal abnormalities involving MLL gene are indicators of poor prognosis of 
the disease 56,57. 
 
Function and structure of MLL 
 
The MLL gene is located on chromosome 11q23.3 and consists of 37 exons 
spanning over 92kb. The around 11.9kb transcript encodes a 430kDa protein 
comprising 3969 amino acids, which is able to bind DNA and methylate histone H3 
lysine 4 (H3K4) through its SET domain. In Drosophila, the trithorax protein, the 
homologue of MLL positively regulates the expression of target genes including 
multiple homeodomain (Hox) genes through H3K4 methylation 58. Similarly, in mice 
the homozygous deletion of the MLL gene is lethal due to disturbed Hox-mediated 
body plan formation, indicating MLL maintained Hox gene expression is crucial for 
embryonic development. MLL-deficient hematopoietic progenitor cells from yolk-sac 
and fetal liver showed impaired colony forming and proliferation activities, suggesting 
MLL also plays an important role in hematopoiesis 59. Furthermore, conditional 
ablation in adult mice demonstrated that MLL is critical to maintain adult 
hematopoietic stem cells 60. 
 
The mature MLL protein consists of two subunits, N-terminal MLL (300/320kDa) and 
C-terminal MLL (180kDa), which are produced through proteolytic cleavage by 
taspase1 and noncovalently associated through the FYRN and FYRC domains 
forming a stable complex 61. In the N terminus of MLL, three short AT?hook motifs 
are supposed to mediate binding to the minor groove of AT-rich DNA. Two speckled 
nuclear localization sites (SNL1 and SNL2) are found immediately C?terminal to the 
AT?hooks followed by a transcriptional repression domain (TRD) including two 
functional subunits, RD1 and RD2, which are retained in all MLL fusions and required 
for transformation by all MLL fusion proteins. RD1 contains the DNA 
methyltransferase (DMT) homology domain including the CXXC zinc finger domain 
 17 
that recruits the polycomb repressor proteins HPC2 and BMI-1, and the corepressor 
CTBP 62. RD2 mediates repression through recruitment of histone deacetylases 
HDAC1 and HDAC2 62. Adjacent localizes a plant homology domain (PHD) zinc-
finger motif that interacts with the nuclear cyclophilin, CYP33 (which negatively 
regulates HOXC8 and HOXC9 transcription). Downstream of two taspase cleavage 
sites is the transcriptional activation (TA) domain, which recruits the transcriptional 
co-activator CBP (CREB-binding protein). The binding of MLL to promoters of HOX 
genes is in connection with CBP mediated acetylation of H3 and H4. Near the C-
terminus of MLL is a SET (Su(var)3-9, enchancer-of-zeste, trithorax) domain that 
possesses histone H3 lysine 4 (H3K4) methyltransferase activity (Fig. II). The SET 
domain can interact with SWI/SNF chromatin remodeling complex and might play a 
direct role in the transcriptional activation of HOX genes 63,64. 
 
 
 
Fig. II. Schematic structure of the MLL protein and MLL fusions. 
Putative functional domains are presented as colored boxes and labeled as follows: AT?hook, 
AT-hook DNA binding motifs; SNL1/2, speckled nuclear localization site1/2; RD, 
transcriptional repression domain; PHD, plant homology domain; TA, transcriptional 
activation domain; SET, Su(var)3-9, enchancer-of-zeste, trithorax domain; CS, cleavage site;  
MLL–PTD, MLL- partial tandem duplication.  
 
 18 
MLL chromosomal abnormality and leukemia 
 
The recurrent chromosomal translocations result in the first 8–13 exons of MLL in-
frame fused with a variety of partner genes. More than 50 MLL fusion partner genes 
have been identified by cytogenetic and molecular genetic analysis, however only a 
few MLL fusions have been functionally studied. 
 
According to differences in cellular location and putative function, some of MLL 
rearrangements can be classified into groups (Table. I) 58. The first group is 
comprised of fusion partner genes encoding the nuclear DNA-binding proteins AF4 
(ALL1 fused gene from chromosome 4), AF9, AF10, ENL (eleven nineteen leukemia 
gene) and ELL (eleven nineteen lysine-rich leukemia gene), which all together 
account for more than 80% of MLL translocation in leukemia patients 54,55.  
 
The second group of MLL fusions involves cytoplasmic proteins such as GAS7, EEN, 
AF1p or Eps15, AF6 and AFX, found in more than 10% MLL rearranged leukemias. 
The common feature of this group of protein is coiled-coil oligomerization domains 
that are important for their transformation potential 65. The third group of fusion 
partners includes septins (SEPT2, SEPT5, SEPT6, SEPT9 and SEPT11), which are 
cytoplasmic proteins playing a role in mitosis and cytoskeletal structure 66. Another 
group of fusion partner proteins are histone acetyltransferases p300 and CBP. MLL 
is fused with these proteins retaining histone acetyltransferase activity, although TA 
domain, which mediates interaction of p300/CBP with wildtype MLL, does not exist in 
MLL fusions 67,68. These two groups of MLL fusions are only observed in 2% of MLL 
associated leukemias. The last group contains only MLL–partial tandem duplication 
(MLL–PTD). MLL–PTD results from a unique MLL rearrangement, in which a variable 
number of exons 5 to 12 are duplicated and inserted before exon 11 or 12. MLL–PTD 
is found in 4-7% normal karyotype AML patients and also often associated with 
trisomy 11 abnormality 69. 
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Table I. Classification of MLL fusions (adapted from ref. 58) 
 
 
 
Since HOX genes are critical effectors of MLL in regulating embryonic development 
and hematopoiesis, they seems also to be important regulators of the leukemogenic 
activity of MLL fusions. Upregulation of HOX gene expression is a common feature of 
MLL rearranged leukemias 57. The mice transplanted of Hoxa9 deficient bone marrow 
cells retrovirally expressing the MLL/ENL fusion failed to develop leukemia 70, 
suggesting an absolute requirement of Hoxa9 for the MLL/ENL induced AML. 
However, Hoxa9 seemed to be dispensable for leukemia induction by the MLL/AF9 
fusion as demonstrated in a knock-in mouse leukemia model 71. For MLL fusion 
proteins containing oligomerization domains such as leucine zippers and ?-helical 
coiled-coil domains, formation of stable form of proteins by oligomerization may be 
crucial constituent of MLL rearrangement associated leukemogenesis. The 
development of leukemia in mice expressing N-terminal MLL fused with beta-
galactosidase indicated that oligomerization mediated by beta-galactosidase may 
confer leukemogenic properties to MLL 72. There is accumulating evidence linking the 
oncogenic activity of many MLL fusion partners to aberrant transcriptional regulation 
through chromatin remodeling. The transformation of myeloid progenitors by 
MLL/CBP involves epigenetic regulation of chromatin accessibility surrounding 
regulatory regions within MLL target genes 73. Binding of DOT1L histone 
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methyltransferase, which methylates lysine 79 residues in histone H3 (H3K79), with 
MLL fusion partner AF10 is essential for MLL/AF10 leukemic activity and suppression 
of DOT1L abolishes MLL/AF10 mediated transformation of hematopoietic progenitors 
74. Interestingly, knockdown of DOT1L also suppressed leukemia induced by a 
knocked-in MLL/AF4 allele 75. The oncogenic activity of MLL/ENL may also implicate 
histone modification, since MLL/ENL increases H3K79 levels on HOXA9 and MEIS1 
promoters 76. The methylation of H3K79 has been shown to be a mark of positive 
transcriptional regulation, and the replacement of H3K4 activity in wild-type MLL with 
H3K79 activity in the MLL fusion complex might represent an unknown mechanism of 
aberrant transcriptional regulation 77. These studies suggested that detailed 
elucidation of the role of MLL in normal and malignant hematopoiesis might result in 
developing new principles for targeted therapeutic intervention 78. 
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MATERIALS AND METHODS 
 
Cell lines: The following human leukemia cell lines were analyzed: MV4;11, acute 
myeloid leukemia (MLL/AF4+, FLT3-ITD+), MOLM13, acute myeloid leukemia  
(MLL/AF9+); EOL1, acute eosinophilic leukemia (MLL-PTD);  THP1, acute monocytic 
leukemia (MLL/AF9+); KOCL44, acute lymphoblastic leukemia (MLL/ENL+), SEM, 
acute lymphoblastic leukemia (MLL/AF4+), KOPN8, acute lymphoblastic leukemia 
(MLL/ENL+), RS4;11, acute lymphoblastic leukemia (MLL/AF4+) and HL-60, acute 
myeloid leukemia. All cells were kept in RPMI 1640 with Glutamine (Invitrogen, 
Carlsbad, CA) plus 10% fetal bovine serum and penicillin/streptomycin at 37°C.  
 
Construction of recombinant retroviral vectors: Full-length human 5’-FLAG-
tagged MN1 cDNA was excised (SacI-HindIII) from pCMVTag2B-MN1 (a kind gift 
from Dr. Paul MacDonald, Cleveland, Ohio) and transferred into the pSL1180 (SacI-
SmaI) cloning vector and further subcloned into pMSCV-IRES/EYFP. The MLL/ENL 
cDNA (a kind gift from Dr. Robert Slany, Erlangen, Germany) was subcloned from 
pMSCV-pgk/neo into pMSCV-IRES/EGFP or pMSCV-pgk/puro using a unique EcoRI 
site. All expression plasmids were verified by extensive restriction digests, and by 
partial sequencing.   
 
Bone marrow infections & transplantation: Bone marrow cells were harvested 
from 6- to 10-week-old [FVB/Nx129/s1]F1 mice 4 days after i.p. injection of 5-
fluorouracil (5-FU) 150 mg/kg (Sigma), and were cultured for 24 hours in RPMI 1640 
supplemented with 10% fetal bovine serum, 10ng/ml of human interleukin-6 (IL-6), 
6ng/ml of murine interleukin-3 (IL-3) and 100ng/ml of murine stem cell factor (mSCF) 
(PeproTech EC, London, UK). HEK293T cells were transiently co-transfected with 
pMSCV retroviral vector and a packaging vector (pIK6), and virus containing 
supernatants were collected after 48h and concentrated by 60 min of centrifugation 
at 14000 rpm, 4°C. Retroviral infections were performed by spinoculation of the cells 
(2500rpm, 90min, 30°C) with retroviral supernatant on two consecutive days. 1x106 
transduced bone marrow cells were injected into the tail vein of lethally irradiated 
(60Co, 950rad) syngenic recipients. For secondary transplantation, the limiting doses 
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of leukemic blasts (from 5x105 to 500) from primary mice were transplanted into 
sublethally irradiated (450rad) recipients by tail vein injection. 
 
Simple sequence length polymorphism (SSLP) based genotyping analysis: 
52 SSLP / Microsatellite marks were used for PCR analysis of 19 mouse autosomes 
(2-3 widely spaced markers for each autosome). Genomic DNA isolated from 
leukemia mice (F1 hybrid mice, one allele from FVB/N and another one from 129/s1) 
was PCR amplified using dye-labeled primers for microsatellite markers. The PCR 
condition is at 94ºC for 15 sec, 55ºC for 15 sec, 72ºC for 30 sec for 10 cycles, 89ºC 
for 15 sec, 55º for 15 sec and 72ºC for 30 sec for 20 cycles. The PCR products were 
analyzed using ABI 3100 genetic analyzer (Applied Biosystems, Foster City, CA, 
USA) according to the manufacturer’s protocol. Genotypes were scored using the 
Genemapper software package version 3.5 and loss of heterozygosity (LOH) was 
determined by measuring the intensity of two alleles (Applied Biosystems, Foster City, 
CA, USA). 
 
Serial replating assay: 104 transduced bone marrow cells were plated in 1ml of 
methylcellulose culture (Stem Alpha.mIE, Stem Alpha, France) containing IL-3, IL-6 
and mSCF. The number of colonies was counted after 7 days. Colonies were 
harvested, and 104 cells were replated in methylcellulose for 4 rounds. 
 
Analysis of transplanted mice: After red cell lysis peripheral blood and bone 
marrow cells were counted and analyzed by using a flow cytometer (Cyan II, Becton 
Dickinson): single cell suspensions were stained with phycoerythrin (PE), or 
allophycocyanin (APC) fluorochromes-labeled c-Kit, Sca1, Gr1, Mac1, B220 and 
CD34 monoclonal antibodies (all from Pharmingen, San Diego, CA). Morphological 
histopathological analysis of peripheral blood, bone marrow, liver and spleen was 
performed using standard procedures. 
 
Retroviral integration cloning by splinkerette PCR: Genomic DNA isolated from 
bone marrow or spleen cells of leukemic mice was digested with NlaIII or MseI for 
12-16 hours, and ligated to the splinkerette linker overnight. The nested PCR was 
performed by using splinkerette linker-specific primers and primers recognizing the 
long terminal repeat of pMSCV 79,80. Amplicons from the second PCR were 
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separated on 2% agarose gel, purified by gel purification kit (Qiagen, Hilden, 
Germany) and subcloned into pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA) prior 
to sequencing, or directly sequenced by using the BigDye Terminator v3.1 chemistry 
and ABI 3130 DNA genetic analyzer (Applied Biosystems, Foster City, CA). Obtained 
sequences were analyzed by using BLAST against the National Center for 
Biotechnology Information (NCBI) mouse genome database. 
 
siRNA knockdown experiments: a) Lentiviral delivered MN1 siRNA: The MN1 
specific shRNA or scramble shRNA lentiviral plasmids (pLKO.1-puro) were 
purchased from Sigma (St Louis, MO). Lentiviral vector packaging was performed 
according to the calciumphosphate method. Briefly, shRNA lentiviral plasmid was 
mixed with envelope plasmid pMD2G, packaging plasmid pMDLg/pRRE and Rev-
expression plasmid pRSV-Rev, and 0.5M CaCl2 was added. The mixture was added 
drop-wise to 2X BES while vortexing at full speed. After 20 minutes incubation, the 
precipitate was slowly added to the 293T cell monolayer. Lentiviral supernatants 
were harvested after 48 hours by spinning at 2500 rpm and filtering through 0.45m 
filter. Lentivirus were further concentrated by spinning through Vivaspin 20 
concentrator (Sartorius Bioloabs, Goettingen, Germany) at 4000rpm 4°C for 30 
minutes, and stored at -80°C. b) Retroviral siRNA knockdown of potential MN1 
targets: 2 cell lines established by serial replating in vitro were grown in RPMI1640 
with growth-factors (IL3, IL6, mSCF) and were transduced with a retrovirus (pSM2) 
expressing miR-siRNA targeting murine gene coding for FLT3 (V2MM_48079, Open 
Biosystems), or CD34 (V2MM_26807). Transduced cells were selected in puromycin 
(2.5-5 ?g/ml) and growth and survival were analyzed in liquid cultures for 5 days and 
methylcellulose for 10 days. Given results are representative for two independent 
experiments in duplicate.  
 
Immunofluorescence: Cells were first fixed with 4% PFA and then cytospined and 
immunolocalization were performed. Cells were permeabilized with 0.5% Triton X-
100 in PBS, treated with RNase and blocking was done in 0.1% Tween-20/PBS 
supplemented with 1% BSA. The MN1 primary antibody (a kind gift from M. Meesters 
& E. Zwarthoff, Rotterdam, The Netherlands) was added for 1 hour incubation at 
room temperature, slides were washed and incubated in the dark for one hour with 
the Alexa Fluor 488 goat anti-mouse antibody (Invitrogen, Carlsbad, CA). PI was 
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used for nuclei staining. Slides were washed and mounted with Fluorsafe Reagent 
(Calbiochem, San Jose, CA). Confocal microscopy was carried on a LSM 510 laser-
scanning microscope (Zeiss, Oberkochen, Germany). 
 
FACS sorting of Granulocyte Macrophage Progenitors (GMPs): The isolated 
bone marrow cells were first stained with the lineage cocktail which contains 
antibodies specific for the following mouse lineage markers: biotinylated rat anti-
mouse CD5, CD11b, CD45R/B220, Ly-6G (Gr-1), and Ter119 (MAGM209, R&D 
Systems). Then cells were stained with a streptavidin Pacific Blue-conjugated 
(Invitrogen), a PE-Cy5-conjugated anti-mouse IL-7R? (A7R34, eBioscience), a PE-
conjugated anti-mouse Fc?RII/III (93, eBioscience), an Alexa Fluor 647-conjugated 
anti-mouse CD34 (RAM34, BD Pharmigen), an APC-conjugated anti-mouse c-Kit 
(2B8, BD Pharmigen), and a PE-Cy7-conjugated anti-mouse Sca-1 (E13-161.7, 
Biolegend) monoclonal antibody. Granulocyte Macrophage Progenitors (GMPs) were 
FACS sorted as IL-7R?– Lin– Sca-1– c-Kit+ CD34+ Fc?RII/IIIhi as described previously. 
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Quantitative RT-PCR: Target validation was performed in triplicate by real-time PCR 
with SYBR-green on an ABI prism 7700 sequence detection system (Applied 
Biosystems, Foster City, CA). For each target the results were normalized to GAPDH 
and given as ??Ct values normalized to MOCK-infected (MSCV-IRES/EYFP) bone 
marrow cells. The results are represented as the mean plus or minus standard 
deviations of 3 independent experiments. The detailed information about 
oligonucleotide primers is given in Table 5. 
 
Gene-expression profiling: In three independent experiments bone marrow cells 
were transduced with MSCV-MN1-IRES/EYFP or empty vector. Seventy-two hours 
after transduction, EYFP-positive cells were FACS-sorted and RNA was isolated by 
ion-exchange chromatography with RNAmini (Qiagen, Hilden, Germany) according to 
the manufacturer’s protocol. cDNA target was synthesized, fragmented, biotin-
labeled using the WT Target Labeling and Control Reagents (Affymetrix, cat. # 
900652, Santa Clara, USA) starting from 200ng total RNA, according to the 
procedure described in the Affymetrix GeneChip Whole Transcript Sense Target 
Labeling Assay Manual, Version 4. The cDNA was fragmented and the resulting 
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fragments of approximately 40-70 nucleotides were monitored with the Bioanalyzer 
using the RNA Nano 6000 Chip (Agilent, Palo Alto, USA). The hybridization cocktail 
containing fragmented biotin-labeled target DNA at a final concentration of 25ng/l 
was transferred into GeneChip Mouse Gene 1.0 ST Arrays (Affymetrix, cat. # 901168) 
and incubated at 45°C on a rotator in a hybridization oven 640 (Affymetrix) for 17 
hours at 60rpm. The arrays were washed and stained on a Fluidics Station 450 
(Affymetrix) by using the Hybridisation Wash and Stain Kit using the Fluidics 
Procedure FS450_0007. The GeneChips were processed with an Affymetrix 
GeneChip Scanner 3000 7G. DAT image files of the microarrays were generated 
using Affymetrix GeneChip Command Console (AGCC, version 0.0.0.676). All 
statistical analysis was performed using GeneSpring GX software (Agilent, Palo Alto, 
USA). Genes were considered as significant whenever the fold change was superior 
to 1.5 and the p-value <0.05. The data discussed in this publication have been 
deposited in NCBI Gene Expression Omnibus (GEO, http://www.ncbi. 
nlm.nih.gov/geo/) and will be accessible through GEO Series accession number 
GSE13189.  
 
Patient samples: Under informed consent by the guardians, seventy-three children 
diagnosed between August 2002 and April 2005 of ALL and fourteen of AML, 
according to the conventional FAB (French American British) and immunological 
criteria, were included in this study. 9 patients that were diagnosed of ALL were 
below one year of age. 78 were aged 1 to 15 years (median age 5.1 years).  On the 
basis of the immunophenotype, sixty-four ALL patients were classified as prepre-B 
(n=10), cALL (n=38), pre-B (n=9), pro B-ALL (n=2), and T-ALL (n=5). Chromosome 
analysis from bone marrow cells was performed according to standard laboratory 
techniques. Definition of a clone and karyotype designation was according to ISCN 
1995. Mononuclear cells were isolated using Ficoll-Hypaque (Pharmacia-LKB, 
Uppsala, Sweden) density gradient centrifugation (BM-MNC).  RNA was extracted 
from BM-MNC at diagnosis and cDNA was synthesized by using random hexamers.  
RT-PCR for TEL/AML1, BCR/ABL, MLL/AF4, E2A/PBX1, AML1/ETO, 
CBFbeta/MYH11 fusion genes was performed as previously described 81. FLT3 
length mutations were determined by sequencing as previously described 82. 
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RESEARCH BACKGROUND 
 
Expression of the class II mutations such as MLL fusions or MOZ/TIF2 in the murine 
bone marrow is able to induce an acute leukemia phenotype that closely resembles 
the human disease in many aspects. In most studies, the transplanted bone marrow 
cells have been transduced with a retrovirus expressing the respective leukemogenic 
fusion oncogene. A leukemic phenotype will develop after a latency period of couples 
of weeks or months. Interestingly, clonality analysis provides evidence that the 
leukemic blasts are composed of one (clonal) or only a few clones (oligoclonal) 
suggesting that additional genetic alterations might have been necessary for 
induction of the full blown disease phenotype. We therefore asked what could be the 
nature of potential functionally collaborating genetic events. In order to identify such 
genetic events for leukemogenesis of AML induced by class II mutations, we used 
the bone marrow reconstitution assay to model MLL/ENL and MOZ/TIF2 induced 
AML in the mouse. As shown previously, MLL/ENL and MOZ/TIF2 lead to the onset 
of AML after a latency of 3-4 months 40,58. As more than 90% of the spleen and bone 
marrow cells are replaced by leukemic blasts in these mice, we were able to isolate 
genetic material (DNA, RNA) from a large number of tumor cells (Fig. 1A). 
 
The homozygous gene mutations at distinct loci such as WT1, FLT3, CEBPA, and 
AML1 were identified in AML patients with uniparental disomy (UPD). Those genes 
are well known as the targets of mutation in AML, and substitution of wild type allele 
with mutant allele caused by loss of heterozygosity (LOH) could act as the second hit 
that would contribute to leukemic transformation 83. Therefore, we first planned to 
perform a genome-wide polymorphism analysis to determine if UPD is also frequently 
associated with leukemic mice. However, by applying a microsatellite PCR-based 
screen as well as a low resolution single nucleotide polymorphism (SNP) array 
approach we were not able to identify additional alterations in 21 murine leukemias 
induced by MLL/ENL or MOZ/TIF2. 
 
Since in our model, a retroviral system was applied to express MLL/ENL or 
MOZ/TIF2 fusion gene in mice, we wondered whether the deregulation of genes 
surrounding proviral insertions could act as collaborating genetic hit and cloned 
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retroviral integration sites in murine leukemias. Retroviral integration cloning strategy 
is a widely applied strategy for identifying oncogenes or tumor suppressor genes 
involved in cancer. The gene adjacent to a provirus can be activated by proviral 
enhancer or promoter insertion as well as post-transcription dysregulation, or 
inactivated by disruption of transcription 84,85. A cell carrying such retroviral 
integration can acquire growth advantage and will be clonally selected to expand out. 
In such a case, those retroviral insertions may also serve as additional hits for multi-
step progression of leukemia driven by the initial mutations 86. 
 
The publication of the mouse genome sequence greatly advanced the large scale 
screening for novel oncogenes or tumor suppressor genes through the isolation of 
proviral insertion sites in the inbred mouse strains (such as AKXD and NFS.V+) that 
produce high level of endogenous murine leukemia viruses (MuLVs), or the strains 
with deficiency of certain tumor suppressor genes were infected with replication 
competent retrovirus, such as murine moloney leukemia viruses (MuMoLVs). The 
experimental data from such screens demonstrated that the genes deregulated by 
retroviral integration could synergize with initial hits, by activation of oncogenes c-
Myc or inactivation of tumor suppressor gene Cdkn2a, and induced leukemia or 
lymphoma in mice 87-90. 
 
There is increasing evidence that the transduction of replication defective retrovirus 
(as applied in our models for transduction of the leukemia-initiating oncogene) may 
also contribute to tumorigenesis through retroviral integration mutagenesis. Evi1 was 
identified as a (proto) oncogene by transducing mouse bone marrow cells with 
replication-incompetent murine stem cell virus (MSCV) expressing only neo, since 
the insertions of MSCV at 5’ of the Evi1 gene led to overexpression of Evi1 and 
immortalization of immature myeloid progenitors 79. The advantage of this strategy is 
that it simplifies the identification of cooperating events through selection, because 
cell populations transformed are often clonal, and replication-defective viral vectors 
already contain an oncogene as the first ‘‘hit’’ 80,91. Using a splinkerette-PCR 
approach, we identified 66 integration flanking genes from 21 murine leukemias 
induced by MLL/ENL (n=10) or MOZ/TIF2 (n=11). We validated the impact of proviral 
integration on expression of these genes by quantitative RT-PCR. Among the 
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positively validated genes, we identified meningioma 1 (MN1) as a potentially 
collaborating oncogene. 
  
The meningioma 1 (MN1) gene was first identified as the target of a sporadic 
balanced chromosomal translocation in a patient with meningioma 92. The absence of 
MN1 expression in the index patients has led to the suggestion that MN1 is a 
candidate tumor suppressor gene. Several studies have proposed that MN1 
presumably acts as a transcriptional cofactor most probably through interaction with 
other transcriptional regulators such as p300/CBP or RXR/RAR 93,94. MN1 was first 
linked to human leukemia after the cloning of the balanced chromosomal 
translocation t(12;22)(p13;q12) found in patients with AML, myelodysplasia (MDS) or 
CML. This translocation leads to the expression of a MN1/TEL fusion that consists of 
almost the entire open reading frame (ORF) of MN1 fused with the DNA binding 
moiety of ETV6 95. Expression of MN1/TEL in the mouse hematopoietic system by a 
conditional knock-in strategy resulted in the formation of T-cell lymphomas as well as 
AML after a long latency suggesting that MN1/TEL, like MLL fusions, is essential but 
not sufficient to induce the disease 96-98. Gene expression profiling studies of a large 
number of human leukemia samples demonstrated that MN1 is deregulated in cases 
with alterations at 3q26 leading to EVI1 overexpression. In addition, elevated MN1 
has been associated with the presence of inv16 leading to a CBF?/MYH11 fusion 99. 
During the time of our study, functional studies have demonstrated that 
overexpression of MN1 alone is able to induce an AML phenotype in mice 100,101. 
Furthermore, high MN1 expression was shown to have negative prognostic impact in 
AML, especially in the absence of common karyotype abnormalities 102. 
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RESULTS 
 
1. A mouse model for class II mutation induced acute leukemia 
 
In order to identify and biologically characterize any cooperating genetic event for the 
development of AML induced by class II mutations, I first established mouse models 
of two well-characterized class II fusion oncogenes MLL/ENL and MOZ/TIF2 known 
to induce acute leukemia when expressed in the mouse bone marrow 40,55. Similar to 
previous studies, transplantation of bone marrow cells retrovirally expressing 
MLL/ENL or MOZ/TIF2 led to induction of acute leukemia phenotype in lethally 
irradiated syngeneic mice after a latency of 2-4 months (Fig. 1 A&B). The disease 
was characterized by high white blood counts, hepatomegaly, splenomegaly, 
lymphadenopathy and extensive bone marrow and organ infiltration, reflecting clinical 
features of AML patients associated with these two fusions (Fig. 1C). 
 
2. Screening for loss of heterozygosity (LOH) in class II mutation 
mediated murine leukemias 
 
Since the homozygous (point) mutations in known tumor suppressor or oncogenes 
resulting from loss of heterozygosity (LOH) has been frequently observed in human 
AML, we wondered whether this mechanism could provide collaborating genetic hits 
in our murine leukemia models. I therefore performed a simple sequence length 
polymorphism (SSLP) based genotyping analysis to screen for LOH in MLL/ENL or 
MOZ/TIF2 induced leukemia in mice ([FVB/N x 129/s1] F1). The F1 offspring used in 
this study were derived from FVB/N strain crossed with the 129/s1 strain, and contain 
alleles from different parental origins that can be distinguished by using distinct 
polymorphic markers. First I examined all 19 mouse autosomes with selected 52 
microsatellite markers known to be polymorphic for both strains, representing 2-3 
widely distributed microsatellie markers per chromosome (Fig. 1D). To increase the 
density of polymorphic markers, we also applied mouse mapping 5K single 
nucleotide polymorphism (SNP) array, whose mapping resolution is narrowed to a 
1cM (~2Mb) region, and the median number of informative markers is 1,500 SNPs 
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across two strains (performed by an external collaborator) (Fig. 1E). However, no 
region of LOH was found in both of the assays from all 21 mice (Fig. 1F), suggesting 
LOH might be rare events in murine leukemias induced by transplantation of bone 
marrow retrovirally expressing MLL/ENL or MOZ/TIF2. It is possible that LOH 
resulted from gene conversion occurring in very small regions of chromosomes 
would be overseen due to the limited density of our screens. Nevertheless, since 
LOH in human leukemia often involves large stretches of DNA, our analysis suggests 
that the large scale of LOH may be not a common event in MLL/ENL or MOZ/TIF2 
induced acute leukemia in mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Mice developed acute leukemia after transplanted with bone marrow expressing 
MLL/ENL or MOZ/TIF2 
A) Schematic illustration of the experiment. B) The transplantation of MLL/ENL or MOZ/TIF2 
transduced bone marrow cells induced acute leukemia in recipient mice after the median 
latency of 64 days or 103 days respectively. C) MLL/ENL or MOZ/TIF2 induced murine 
leukemias were characterized as extensive infiltration of leukemic blasts in spleen, liver, 
skeletal muscle, kidney and lung. D) The microsatellite markers used for the genome-wide 
allelotyping. E) The mapping panel of Affymetrix GeneChip Mouse Mapping 5K SNP Kit. F) 
The PCR products amplified using microsatellite markers are separated by capillary 
electrophoresis and read by a DNA sequencer. The height of each major peak in 
electrogram indicates the amount of PCR products of each allele. The equal height of two 
peaks means no LOH occurs. One result was taken as a representative. 
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3. Hunting potential cooperating genetic events through retroviral 
insertion sites cloning 
 
To gain more information about potential collaborative genetic events in the class II 
mutation mediated leukemogenesis, I analyzed retroviral integration sites from 10 
MLL/ENL and 11 MOZ/TIF2 mice using a splinkerette PCR technique. The assay 
was performed with DNA from leukemic blasts from each animal in two independent 
experiments. The visualized PCR products were purified and sequenced, and the 
integration site nearest 5’ and 3’ annotated genes were determined (Fig. 2A). In total, 
I was able to identify 66 flanking genes from 21 leukemic animals and among them, 
21 genes were common integration sites (CIS) flanking genes (Table 1&2). CISs 
mean the certain genomic regions that are targeted by retroviral integration in more 
than one tumor and are thus likely to encode a disease gene 103. 
 
To confirm that genes flanking proviral integrations might be dysregulated, we 
examined the expression levels of some genes that have been previously linked to 
cancer by quantitative RT-PCR analysis. As shown in Fig. 2B, quantitative RT-PCR 
analysis revealed that Tcf7, Tnfrsf1, Mn1, Lhx2 were all up-regulated, and Pur-alpha, 
Ppp2r5c, Runx3, Socs1 as well as Prdm2 were down-regulated in the animals 
carrying the respective integration when comparing with healthy controls or other 
leukemic mice without the corresponding integration.  
 
PRDM2 is a member of PR domain-containing protein family, and encoded by 
retinoblastoma protein-interacting zinc finger gene (RIZ). PRDM is a family of 
transcriptional regulators that modulate cell differentiation, growth and apoptosis. A 
common feature of the PRDM gene family is that they can produce 2 types of 
transcripts that differ in the presence or absence of the PR domain (the PRDI-BF1-
RIZ1 homologous region). Noteworthily, the products keeping PR-domain have anti-
tumorgenic potential and are often down-regulated in cancer cells, whereas the 
products without PR-domain may act as oncogene and are over-expressed in tumor 
tissue 104. EVi1 and PRDM16 also belong to PRDM family. Neal Copeland’s group 
has shown that in 37 murine hematopoietic cell lines immortalized by an “empty” 
(carrying no transgene) MSCV retrovirus (that is used here), 7 lines contained MSCV 
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integrations in the first 2 intron of Evi1 and another 13 lines contained integrations in 
the first intron of Prdm16, which promoted expression of transcript variants lacking 
PR-domain. The PRDM2/RIZ gene produces two mRNA and protein products 
through alternative promoters, RIZ1 that contains the PR domain with 
methyltransferase activity, and RIZ2 that lacks this domain. RIZ1, but not RIZ2, has 
been shown to have tumor suppressor activity, and altered RIZ1/RIZ2 expression 
has been found in some human acute myeloid/lymphoid leukemias 105.  
 
When we performed PCR using primers located in the 6th exon of Prdm2, the 
observed mRNA level of Prdm2 were remarkably high, which was totally contrary to 
result using primers covering the region of PR-domain (Fig. 2C). Since exon 6 is 
located downstream of PR-domain, our results indicated that the insertion of 
retrovirus disrupted production of transcripts of Riz1, but led to accumulation of Riz2 
products, which might contribute to oncogenic expansion of MOZ/TIF2 transduced 
cells. The microsatellite PCR analysis of Prdm2 surrounding regions showed that 
wild type allele was not replaced by proviral integrated allele, suggesting the DNA 
methylation of promoter region may be the reason leading to inactivation of 
expression of Prdm2 in wild type allele. 
 
Many of the genes flanking MLL/ENL or MOZ/TIF2 carrying proviral integrations have 
been functionally linked to cancer biology. In order to test their leukemic transforming 
potentials in vitro, we cloned the cDNAs of some of these target genes including 
PRDM2, LHX2, FLT3L, BCOR, SEI1, SEI3 and MN1 into MSCV virus and 
overexpressed them in murine bone marrow cells. We also tested their impact on 
cellular self-renewal capacity in serial replating assays. As shown in Fig. 2 D&E, 
among these 7 genes, MN1 overexpression significantly enhanced cellular growth of 
bone marrow cells and increased the resistance to deprivation of cytokines in 
medium. Moreover, only overexpression of MN1 resulted in increased serial replating 
capcity and still formed colonies in the third round of replating. These observations 
suggested that deregulated expression of MN1 might act as a collaborating genetic 
event in MLL/ENL mediated leukemogenesis.  
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Fig.2. Identification of cooperating oncogenes by cloning of retroviral insertion sites in 
MLL/ENL and MOZ/TIF2 murine leukemias. 
A) Schematic illustration of the splinkerette PCR strategy. B) mRNA expression levels of 
retroviral integration flanking genes in MLL/ENL and MOZ/TIF2 leukemic mice. Relative 
expression levels of target genes were normalized to GAPDH expression in the same 
sample, calibrated to gene expression in normal murine BM and given as ??Ct value. Black 
bars represent the leukemic mice carrying corresponding integrations, and grey bars 
represent irrelevant leukemic mice. C) Insertion of retrovirus in Prdm2 gene interrupted 
expression of Riz1, but promoted production of Riz2 that lacks PR-domain. Murine leukemia 
MT3 harbors a retroviral integration site in Prdm2 gene. D) Serial replating assay of murine 
bone marrow cells overexpressing retroviral integration target genes in methylcellulose. E) 
Growth curve of murine bone marrow cells overexpressing retroviral integration target genes 
in liquid culture with or without cytokines. MT means murine leukemia induced by MOZ/TIF2. 
 
4. Meningioma 1 (MN1) as a potential cooperating oncogene in 
MLL/ENL induced murine leukemia 
 
In the MLL/ENL leukemia mouse no.10 (ME10), I found the proviral insertion sites 
adjacent to several proto-oncogenes or tumor suppressor genes including Mgat5, 
Socs7, Ppp2r5c and Mn1. To validate their potential impact, I firstly compared the 
expression levels of those genes in ME10 with 5 other MLL/ENL leukemias and a 
control sample pooled from the bone marrow from 5 normal mice. The expression of 
Socs7 and Ppp2r5c was lower in ME10 than normal and other leukemic mice, 
whereas Mn1 expression was significantly up-regulated by the MSCV-MLL/ENL 
provirus insertion (Fig. 3 A&B). During our investigation the Mn1 locus has been 
reported as a recurrent integration site in mouse leukemia models induced by 
reconstitution of bone marrow retrovirally expressing leukemogenic oncogenes 
(mutant AML1, NUP98/HOX) that might be functionally linked to MLL fusions 106,107. 
We therefore focused on MN1 for further studies.  
 
The clonal contribution of the MN1 targeting integration was determined by plating 
leukemic blasts from this respective MLL/ENL leukemia (ME10) in semi-solid medium 
and determined the integration sites by PCR. The integration near Mn1 locus was 
predominant and could be detected in 12 out of 20 colonies, 3 colonies harbored the 
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integration targeting Mgat5, and 5 had two insertions targeting Socs7 and Ppp2r5c 
(Fig. 3C). Interestingly, after a second round of plating, an increase of colonies with 
the Mn1 integration to 14 out of 20 was found. This observation suggested that 
overexpression of MN1 by the proviral integration supports the self-renewal of the 
respective clones. Retroviral expression of MGAT5 or know-down of PP2R5C by 
siRNA did result in aberrant self-renewal and growth advantage in liquid cultures as 
shown in MN1 transduced cells (Fig. 3D&E). These observations suggested that 
MN1 has oncogenic activity in primary bone marrow cells and might functionally 
collaborate with the MLL/ENL fusion in the development of the acute leukemia 
phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3. MN1 acts as a putative cooperative oncogene in MLL/ENL induced mouse 
leukemia 
A) Schematic representation of the integration sites of the MSCV-MLL/ENL provirus adjacent 
to the MN1 gene locus. B) mRNA expression levels of genes in the proximity of retroviral 
integration in 5 MLL/ENL leukemia mice. Relative expression levels of target genes were 
normalized to GAPDH expression in the same sample, calibrated to gene expression in 
normal murine BM and given as ??Ct value (* means not applicable). C) Clonal composition 
of the proviral integrations in “ME 10”. 20 colonies were analyzed by integration specific PCR. 
MN1 was the most predominant integration present. D & E) Overexpression of MN1 led to 
enhanced self renewal activity as shown in serial replating assays (D) and cellular 
proliferation in liquid cultures (E). 
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5. Elevated MN1 expression levels cooperate with MLL/ENL in 
murine leukemogenesis 
 
In order to experimentally address the hypothesis that MN1 might cooperate with 
MLL/ENL in murine leukemia, I performed a series of bone marrow transplant 
experiments. Hereby, I reconstituted lethally irradiated mice with bone marrow 
transduced with retrovirus expressing MLL/ENL, MN1 or both. For co-expression 
bone marrow cells were first transduced with the virus encoding MLL/ENL followed 
by a second transduction with the MN1 expressing virus shortly after. Mice 
reconstituted with MLL/ENL (n=10) expressing bone marrow all developed lethal 
acute leukemia after a median latency of 64 days (Fig. 4A). Analogous to previous 
studies, all mice with MLL/ENL induced leukemia strongly mimicked the human 
disease with elevated white blood cells, and infiltration in hematopoietic organs such 
as liver, spleen and bone marrow (Table 3). Reconstitution with MN1 expressing 
bone marrow led to the development of an acute leukemia phenotype after a median 
latency of 100 days. The disease was characterized by elevated white blood cells 
count and the presence of leukemic blasts in liver, spleen, and bone marrow. 
Leukemic blasts from 5 mice analyzed expressed c-Kit and Gr1/Mac1 but no 
expression of markers like B220, TER119 or CD3 was observed (Fig. 4B). 
Interestingly, in some cases the MN1 containing provirus was inserted near the MN1 
locus most probably resulting in further up-regulation of MN1 expression (Table 4). 
 
In contrast to MLL/ENL or MN1 alone, reconstitution of bone marrow co-transduced 
with virus encoding MLL/ENL and MN1 induced an aggressive AML-like disease after 
a significantly shorter median latency of only 35 days post transplantation (Fig. 4A). 
The disease was characterized by very high white blood cell counts and excessive 
infiltration in multiple organs such as bone marrow, spleen, liver, kidney or lung 
(Table 3, Fig. 4C). Leukemic cells expressed both MLL/ENL and human MN1 as 
determined by RT-PCR (Fig. 4D). Leukemic blasts from MLL/ENL + MN1 disease 
expressed higher levels of c-Kit and CD34, but decreased levels of Gr1/Mac1 as 
compared to blasts from MLL/ENL induced disease (Fig. 4B). These in vivo 
observations suggested that MN1 could act as functional collaborator to MLL/ENL in 
murine leukemogenesis. No change in the latency of the disease development was 
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observed when bone marrow was co-transduced with MLL/ENL virus and an empty 
control virus (MSCV-EGFP), and such collaboration has not been observed between 
MOZ/TIF2 and LHX2 that was found to be up-regulated by the integration of the 
MOZ/TIF2 expressing provirus (data not shown). 
 
Leukemic blasts overexpressing MLL/ENL and MN1 showed an increased 
clonogenic growth potential in methylcellulose cultures when compared to leukemic 
cells induced by MLL/ENL or MN1 alone (Fig. 5A). To address the in vivo 
significance of this observation, I performed a series of secondary transplantation 
experiments. As shown in Fig. 5B, transplantation of 5 x105 MLL/ENL leukemic 
blasts into sublethally irradiated recipients resulted in AML after a median latency of 
36 days. In contrast, transplantation of the same number of MLL/ENL + MN1 
leukemic cells resulted in AML after a significantly reduced latency (19 days, 
p=0.005). Further transplantations of dilutions of leukemic blasts showed that in 
contrast to MLL/ENL + MN1 leukemia, 2000 MLL/ENL blasts were not sufficient to 
induce the disease in all the recipients. These experiments provided strong evidence 
that MN1 could functionally collaborate with MLL/ENL and suggested that MN1 
overexpression might lead to expansion of a leukemia-initiating cell population. 
 
 
 
 
 
Fig.4. MN1 cooperates with MLL/ENL in murine leukemogenesis 
A) Co-expression of MN1 and MLL/ENL induced acute leukemia in mice after a significantly 
shorter latency (median latency: 35 days) than MLL/ENL (64 days) or MN1 alone (100 days) 
(p< 0.001). B) Expression of cellular surface markers in murine acute leukemia induced by 
MLL/ENL, MN1 and MLL/ENL + MN1 was analyzed by flow cytometry. MLL/ENL + MN1 
expressing leukemic blasts are characterized by high levels of Gr1/Mac1, c-kit and CD34. C) 
Histological analysis showed extensive infiltration of leukemic blasts in multiple organs 
including spleen (top panel), liver (middle panel), and skeletal muscle (lower panel) of mice 
transduced with MN1 or MLL/ENL + MN1. D) mRNA expression of MLL/ENL and MN1 in 
transplanted mice as shown by RT-PCR using primers covering the MLL/ENL breakpoint 
(upper row), human MN1 (middle row) and GAPDH (lower row). Two from each type of mice 
were taken as representatives. 
 47 
 
 
 
 
 
 
 48 
 49 
 50 
 
 51 
Previous studies suggested that MLL fusion genes not only transform hematopoietic 
stem cells, but are also able to block differentiation and to provide aberrant self-
renewal to committed hematopoietic progenitor cells including granulocyte 
macrophage progenitors (GMPs), common myeloid progenitors (CMPs) and/or 
common lymphoid progenitors (CLPs) 34,108. The significantly shorter latency in 
conjunction with a more immature, “stem-cell like” phenotype leukemia suggested 
that overexpression of MN1 might lead to an expansion of the MLL targeted leukemic 
progenitor population. It’s worth noting that in normal bone marrow the highest levels 
of MN1 expression were found in GMPs proposed to be potential targets of MLL 
fusion genes 100. Therefore, we first compared the GMP populations in leukemic mice 
induced by MLL/ENL, MN1 or MLL/ENL + MN1. As shown in Fig. 5C, MLL/ENL + 
MN1 leukemia was characterized by a significant expansion of the GMP population 
as 20 times more than MLL/ENL. 
 
In order to test the possibility that co-expression of MN1 expression increased the 
leukemic stem cell compartment, we isolated GMPs from MLL/ENL and MLL/ENL + 
MN1 leukemic mice and transplanted identical numbers of Leukemic-GMPs (L-GMPs) 
into sublethally irradiated hosts. As shown in Fig. 5D, transfer of 1000 L-GMPs from 
MN1 + MLL/ENL leukemia reproduced the leukemic phenotype in all recipients after 
a median latency of 34 days. In contrast, an identical number of L-GMPs from 
MLL/ENL leukemia reproduced the disease only in some animals after a significantly 
prolonged latency period of 42 days (P< 0.05). These experiments strongly support 
the idea of functional collaboration of MN1 with MLL/ENL at the level of GMP cell 
population with leukemia-initiating potential. 
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Fig.5. Co-expression of MN1 with MLL/ENL increases the leukemia initiating-cell pool 
A) Increased colony formation in methylcellulose of blasts from leukemic mice induced by the 
co-expression of MN1 with MLL/ENL as compared to MLL/ENL or MN1 alone. Error bars 
represent standard deviations of three independent experiments. B) Secondary 
transplantation with limiting dose of blasts from MLL/ENL or MLL/ENL+ MN1 leukemia mice. 
C) Increased leukemic GMP (L-GMP) population in MLL/ENL + MN1 leukemic mice as 
detected by flow cytometry and was gated as IL7R-, Lin-, c-Kithigh, Sca1-, Fc?RII/IIIhigh and 
CD34+ fraction. The frequency of L-GMPs in MLL/ENL + MN1 mice is about 8.4% (19.1% x 
52.3% x 84.1%), whereas it is about 20 times lower (0.34%) in MLL/ENL mice. D) Recipient 
mice were transplanted with GMP population isolated from MLL/ENL or MLL/ENL+ MN1 
leukemia mice. Median latency for disease development after transplant of 1000 MLL/ENL 
GMPs was 42 days; and 34 days for 1000 MLL/ENL + MN1 GMPs (p< 0.05). 
 
6. Determination of presumptive MN1 targets in hematopoietic 
system 
 
As MN1 has been proposed to act primarily as a transcriptional co-regulator in 
hematopoietic cells we sought to obtain some insights about the MN1-regulated 
oncogenic gene expression program. Thus, we compared the gene expression 
profiles of primary murine bone marrow cells transiently overexpressing MN1 
(MSCV-MN1-IRES/EYFP) with cells transduced with a control vector (MSCV-
IRES/EYFP) by using oligonucleotide arrays (Fig. 6A). As shown in Fig. 6B and 
Table 6, transient over-expression of MN1 resulted in ?1.5 fold up-regulation of 831 
genes and down-regulation of 268 genes (p<0.05). As we asked for putative targets 
that might be involved in the leukemogenic activity of MN1, we selected genes that 
were more than two-fold up-regulated and previously functionally linked to malignant 
hematopoiesis and validated their expression levels by quantitative PCR analysis. 
DLK1, FLT3, CD34, ANGPT2, MAP2K1IP1, HLF, PRNP, and MEIS1 were expressed 
at higher levels, and LIF and CRISP1 at lower levels in MN1 expressing cells as 
compared to mock-transduced mouse bone marrow (Fig. 6C). We next determined 
the expression levels of these genes in blasts from mouse leukemias induced by 
MN1, MLL/ENL or co-expression of MLL/ENL and MN1. In most murine samples, 
elevated expression levels of DLK1, CD34, FLT3, HLF were significantly associated 
with the presence of elevated expression of MN1 (Fig. 6D). 
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Fig.6. Searching for putative MN1 target genes in murine bone marrow cells  
A) Schematic illustration of the experiment. B) The differential expression patterns between 
bone marrow progenitor cells transiently expressing human MN1/EYFP and cells transiently 
expressing EYFP are visualized as a heat map. Gene expression signature of bone marrow 
cells 72 hours after transduction with MN1-expressing retrovirus was identified by 
unsupervised analysis using the hierarchic clustering method. C) Quantitative RT-PCR-
based validation of the up- and down-regulated expression of selected genes upon transient 
MN1 overexpression.  A complete list of up- and down-regulated genes is given in Table 6. D) 
Quantitative RT-PCR analysis of the expression of selected genes in murine blasts from 
leukemia induced by expression of MN1, MLL/ENL or MLL/ENL and MN1. The expression 
levels of target genes were normalized to GAPDH, and given as ?Ct value relative to MOCK 
(MSCV-EYFP) transduced control cells (in vitro) or bone marrow from mice transplanted with 
MOCK-transduced cells (in vivo).  
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In order to validate these putative MN1 target genes in human leukemia, we 
compared their expression in a set of pediatric acute leukemia cases (including 7 B-
ALL, 6 AML, 8 infant leukemias, 6 T-ALL) with elevated expression of MN1 versus 
those with low or absent MN1 expression levels (as found in normal bone marrow).  
As shown in Fig. 7A, we found remarkably higher expression levels of CD34 
(p=0.0021) and FLT3 (p=0.03) in a cohort of pediatric leukemias with significantly 
elevated MN1 levels (p<0.0001) than in cases with low or undetectable MN1 levels. 
Expression of DLK1 and HLF1 correlated with MN1 in certain cases but was not 
significant as a cohort (data not shown). In contrast to the murine samples (Fig. 6D), 
no association of MEIS1 with elevated MN1 levels was observed (Fig. 7A). 
 
To further investigate the significance of CD34 and FLT3 up-regulation in MN1 
overexpressing cells, we reduced expression of these genes by the respective 
siRNAs in 2 cells lines immortalized by MN1 or MLL/ENL. Flow cytometric analysis 
72 hours post transduction showed a 50-60% reduction of CD34 and FLT3 surface 
expression by siRNA mediated knockdown (Fig. 7B). Decreased levels of CD34 or 
FLT3 resulted in a significant reduction of colony formation of MN1 expressing cells, 
whereas knockdown of CD34 had no impact on the clonogenic growth of MLL/ENL 
expressing cells (Fig. 7C). In liquid culture, under continuous selection, we could only 
observe growth reduction of MN1 but not of MLL/ENL cells (Fig. 7D). These results 
suggest that CD34 and FLT3 could be important mediators of the leukemogenic 
activity of MN1. 
 
 
Fig.7. Expression of putative MN1 target genes in pediatric acute leukemia  
A) Quantitative RT-PCR analysis of expression of selected targets in pediatric leukemia 
cases with high or low MN1 expression, as well as in different types of childhood leukemia 
including B-ALL (n=7), Infant ALL (n=8), AML (n=6) and T-ALL (n=6). The expression levels 
of target genes were normalized to GAPDH, and given as ?Ct value relative to healthy 
controls (bone marrow). B) siRNA-mediated knockdown of CD34 and FLT3 in murine 
hematopoietic progenitor cells immortalized by MN1 or MLL/ENL overexpression as 
assessed by flow cytometry. C & D) Impact of siRNA-mediated knockdown of CD34 and 
FLT3 in MN1 and MLL/ENL immortalized cells on clonogenic growth in methylcelluose (C) 
and proliferation in liquid cultures (D). 
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7. MN1 expression in pediatric acute leukemia 
 
Since the role of MN1 in pediatric leukemia has never been addressed, we 
determined the MN1 mRNA expression levels in a panel of 64 patients with acute 
lymphoblastic leukemia (ALL) including 10 prepre-B-ALL, 38 common ALL (cALL), 9 
pre-B-ALL, 2 pro-B-ALL, and 5 T-ALL cases. No significant MN1 expression could be 
detected in T-ALL cases. Compared to the normal bone marrow, slightly elevated 
levels were seen in the pre-B-ALL samples. Interestingly, several cases of the more 
immature B-cell ALL showed significantly elevated levels of MN1 expression even 
higher than the ME-1 cell line carrying an inv16 previously shown to overexpress 
MN1 100. Surprisingly, the highest MN1 expression levels were observed in ALL 
cases originating from early B-cell precursors (Fig. 8A). MN1 expression was also 
determined in a group of 14 childhood AML cases. Significantly elevated MN1 levels 
were found in 3 patients (Fig. 8B). No correlation with the presence of FLT3-ITD 
mutations was observed in this small group of patients. We also analyzed MN1 
expression in a panel of 9 cases of infant acute leukemia associated with MLL 
translocations. Interestingly, all cases expressed higher MN1 levels than a pooled 
sample of 5 normal bone marrows (Fig. 8C). Our results showed that, in pediatric 
leukemia, elevated MN1 expression is not limited to disease of the myeloid lineage, 
and that increased MN1 expression is not limited to cases carrying inv16, but is also 
found in leukemia harboring MLL fusion genes.  
 
 
 
 
 
 
Fig.8. MN1 expression in pediatric acute leukemia 
A) MN1 mRNA expression in childhood ALL samples assessed by quantitative RT-PCR. B) 
MN1 mRNA expression in childhood AML samples detected by quantitative RT-PCR. C) 
MN1 mRNA expression in infant leukemia samples with different MLL translocations 
detected by quantitative RT-PCR. Expression levels in patient samples are depicted as fold 
change calibrated to average MN1 expression in 5 pooled normal human BM samples. 
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8. RNA interference-mediated knockdown of MN1 expression 
impairs the growth of human acute leukemia cells 
 
Although elevated MN1 expression has been reported to provide negative prognostic 
information in adult AML cases102, the contribution of MN1 to the biology of any 
leukemic cell clones remained unclear. To functionally study the role of MN1 in 
human leukemia, we first determined MN1 expression levels in a panel of acute 
leukemia cell lines (HL60, MV4;11, MOLM13, KOCL44, RS4;11, SEM, KOPN8, EOL-
1, THP1). As shown in Fig. 9A, MN1 expression was detected in THP1, MOLM13, 
KOCL44, RS4;11 but not all MLL fusion positive cell lines. Findings on the mRNA 
level were also reflected on the protein levels as shown by immunofluorescence 
staining of MN1 in MOLM13 and SEM cells (Fig. 9B). To study the role of elevated 
MN1 expression for maintenance of the malignant cell phenotype, we transduced the 
cells with lentivirus expressing either MN1-specific or scramble siRNAs. A series of 
control experiments showed that four cell lines of the panel (HL60, MOLM13, RS4;11, 
THP1) could be efficiently lentivirally transduced (not shown). Expression of MN1 
siRNAs resulted in a reduction of MN1 expression of >50% in HL60, MOLM13 and 
THP1 and 25-30% reduction in RS4;11 (Fig. 9C). RNAi-mediated knockdown of MN1 
expression resulted also in a significant decrease of clonogenic growth (in 
methylcellulose) of THP1 and MOLM13 and to a lesser extent of RS4;11 (Fig. 9D). 
Likewise, decreased growth potential of the cell lines expressing MN1 siRNAs was 
also observed in liquid cultures (Fig. 9E). The growth of HL-60 cells that express very 
low levels of MN1 was not affected by MN1 knockdown. Cell cycle analysis of THP1 
and MOLM13 cells showed that MN1-knockdown led to a significant increase of cells 
in G0/G1 associated with a reduction of cells in G2/M and S phase (Fig. 9F). The 
observed reduced growth rate was not associated with an increase of apoptotic cell 
death determined by flow cytometric analysis (Fig. 9G). Taken together, these results 
demonstrated for the first time that increased MN1 expression provides a positive 
growth signal to human leukemic cells. 
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Fig.9. Knockdown of MN1 expression impairs the growth of human acute leukemia 
cells with elevated MN1 levels  
A) MN1 mRNA expression level in human acute leukemia cell lines determined by 
quantitative RT-PCR. Relative MN1 expression was normalized to GAPDH expression in the 
same sample, and shown as ??Ct value using HL-60 cells as a calibrator. B) Detection of 
MN1 protein expression in cell lines by immunofluorescence staining (Objective 40x/1.30). 
(MN1= MN1 recognized by MN1-specific antibody bound with green fluorescence labeled 
secondary antibody. PI= nuclear staining by propidium iodide, NORM = phase contrast) C) 
Efficacy of the lentiviral-mediated MN1 knockdown by human MN1 specific siRNA assessed 
by quantitative RT-PCR. D) MN1 knockdown impaired clonogenic growth (in methylcellulose) 
of THP1, MOLM13 and RS4;11 cell lines expressing high levels of MN1 but not HL-60 
expressing very low levels of MN1. E) MN1 knockdown impaired proliferation of THP1, 
MOLM13 and RS4;11 cell lines but not HL-60 in liquid culture. F) Cell cycle analysis revealed 
that MN1 knockdown resulted in increased cells in G0/G1 phase and less cells in S and G2/M 
phase. G) THP-1 cells were infected with lentivirus expressing MN1 specific siRNA or 
scramble siRNA and then stained with PO-PRO-1 and 7-AAD dyes. Apoptotic cells were 
indicated as PO-PRO-1 positive and 7-AAD negative cell populations by flow cytometric 
analysis. Results shown in C-E are compared to lentiviral infection with a scramble siRNA 
control. Open bars= scramble siRNA; black bars= MN1 specific siRNA. 
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Table 5. Oligonucleotide primers and resulting products used for RT-PCR analysis. 
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Table 6. ?1.5 up- or down-regulated genes (p<0.05) upon transient (72h) 
overexpression of MN1 in primary murine bone marrow cells as assessed by gene 
expression profiling. 
refseq Gene symbol 
Fold 
change 
Regu-
lation 
refseq Gene symbol 
Fold 
change 
Regu- 
lation 
NM_001002927 Penk1 8.89 up NM_028493 Rhobtb3 2.69 up 
NM_029529 Slc35d3 5.56 up NM_008587 Mertk 2.68 up 
NM_007993 Fbn1 5.29 up NM_053110 Gpnmb 2.68 up 
NM_173024 Serpina3b 5.12 up NM_133222 Eltd1 2.68 up 
NM_017469.3 Gucy1b3 4.83 up XM_619639|XM_984786 Tns1 2.66 up 
NM_010052 Dlk1 4.66 up NM_139197 Gbgt1 2.65 up 
NM_175406 Atp6v0d2 4.64 up NM_009822 Runx1t1 2.64 up 
NM_010050 Dio2 4.43 up NM_019971 Pdgfc 2.63 up 
NM_001007460 Zdhhc23 4.32 up NM_030209 Crispld2 2.63 up 
NM_011329 Ccl1 3.93 up NM_016846 Rgl1 2.62 up 
NR_001586|NR_003596 Speer1-ps 3.93 up  Folr2 2.62 up 
NM_021443 Ccl8 3.88 up NM_010329 Pdpn 2.60 up 
NM_011170 Prnp|Prnd 3.76 up NM_010605 Kcnj5 2.59 up 
NM_024469 Bhlhb3 3.75 up NM_008372 Il7r 2.59 up 
NM_021896 Gucy1a3 3.70 up NM_001081298 Lphn2 2.59 up 
NM_007553 Bmp2 3.69 up NM_025638 Gdpd1 2.58 up 
 EG545728 3.58 up NM_011520 Sdc3 2.56 up 
NM_172589 Lhfpl2 3.56 up NM_201518 Flrt2 2.55 up 
NR_003596|NR_001586 Grm3|LOC623849 3.53 up NM_008620 Gbp4 2.55 up 
 D14Ertd668e 3.51 up NM_007802 Ctsk 2.54 up 
NM_011426 Siglec1 3.50 up NM_007643 Cd36 2.54 up 
NM_138741 Sdpr 3.45 up NM_008885 Pmp22 2.53 up 
NM_013703 Vldlr 3.43 up NM_011333 Ccl2 2.52 up 
NM_026037|NM_001083341 Mboat2 3.42 up NM_001081298 Lphn2 2.51 up 
NM_012008 Ddx3y 3.42 up NM_009696 Apoe 2.50 up 
NM_080555 Ppap2b 3.37 up NM_008719 Npas2 2.49 up 
NM_133974 Cdcp1 3.36 up NM_028199 Plxdc1 2.49 up 
NM_010612 Kdr 3.35 up NM_023785 Ppbp 2.48 up 
NM_001002268 Gpr126 3.34 up NM_007405 Adcy6 2.47 up 
NM_007572 C1qa 3.24 up NM_177698|NM_030263 Psd3 2.47 up 
NM_031159 Apobec1 3.23 up NM_013612 Slc11a1 2.47 up 
NM_019511 Ramp3 3.16 up NM_026346 Fbxo32 2.47 up 
 AI427515 3.13 up NM_010008 Cyp2j6 2.46 up 
NM_153170 Slc36a2 3.11 up NM_153422 Pde5a 2.45 up 
NM_007574 C1qc 3.08 up NM_001081298 Lphn2 2.44 up 
NM_172563 Hlf 3.05 up NM_001033476 Ahnak2 2.44 up 
NM_010229 Flt3 3.02 up NM_009255 Serpine2 2.43 up 
NM_001081235 Mn1 2.99 up NR_003568 Gpr137b-ps 2.42 up 
NM_012011 Eif2s3y 2.99 up  Fabp5 2.40 up 
NM_007484 Rhoc 2.94 up NM_133754 Fblim1 2.39 up 
NM_010512|NM_184052 Igf1 2.92 up  Mmrn1 2.39 up 
 Slamf7 2.92 up NM_010634 Fabp5 2.39 up 
NM_011175 Lgmn 2.91 up NM_008512 Lrp1 2.39 up 
NM_015800 Crim1 2.89 up NM_134158 Cd300d|Cd300a 2.38 up 
 LOC626578 2.89 up NM_009484 Uty 2.38 up 
 Robo3 2.85 up NM_008881 Plxna1 2.38 up 
NM_008198 Cfb 2.79 up NM_009984 Ctsl 2.38 up 
NM_145459 Zfp503 2.78 up NM_013654 Ccl7 2.37 up 
NM_013454 Abca1 2.78 up NM_001081298 Lphn2 2.37 up 
NM_008534 Ly9 2.77 up NM_009777 C1qb 2.37 up 
NM_022420 Gprc5b 2.76 up NM_029509 5830443L24Rik 2.36 up 
NM_028122 Slc14a1 2.75 up NM_008594|NM_001045489 Mfge8 2.35 up 
NM_133733 9030425E11Rik 2.74 up NM_145437 4732429D16Rik 2.34 up 
NM_024406 Fabp4 2.72 up NM_016900 Cav2 2.33 up 
 Fer1l3 2.72 up NM_027763 Treml1 2.32 up 
NM_207676|NM_207675 Cadm1 2.71 up NM_010186 Fcgr1 2.31 up 
NM_011407 Slfn1 2.30 up NM_178695 Prrg4 2.31 up 
NM_001081298 Lphn2 2.28 up NM_008209 Mr1 2.31 up 
NM_009141 Cxcl5 2.28 up NM_009763 Bst1 2.30 up 
NM_025629 Adamtsl5 2.25 up NM_021436 Tmeff1 2.07 up 
NM_019932 Cxcl4 2.25 up NM_020561 Smpdl3a 2.07 up 
NM_009917 Ccr5 2.24 up NM_011125 Pltp 2.06 up 
NM_009917 Ccr5 2.24 up NM_007417 Adra2a 2.06 up 
NM_009345|NM_001043228 Dntt 2.24 up NM_053014 Agpat3 2.06 up 
NM_013754 Insl6 2.22 up NM_007388 Acp5 2.05 up 
NM_010172 F7 2.22 up NM_008509 Lpl 2.05 up 
NM_021412 Mmp19 2.22 up NM_011716 Wfs1 2.05 up 
NM_145509 5430435G22Rik 2.22 up  EG432555 2.05 up 
NM_011410 Slfn4 2.21 up  C130060K24Rik 2.05 up 
NM_026018 Pdzk1ip1 2.21 up NM_019919|NM_206958 Ltbp1 2.04 up 
NM_008149 Gpam 2.21 up NM_008528 Blnk 2.04 up 
NM_011595 Timp3 2.21 up NM_144783 Wt1 2.04 up 
NM_133871 Ifi44 2.20 up NM_033144 septin 8 2.04 up 
NM_133987 Slc6a8 2.20 up NM_172786 Il20ra 2.04 up 
 Tmem86a 2.19 up NM_007932 Eng 2.04 up 
NM_010867|NM_001083934 Myom1 2.19 up NM_011854 Oasl2 2.04 up 
NM_001039676 Slc39a2 2.19 up NM_030066 Armcx1 2.04 up 
NM_010745 Ly86 2.18 up NM_172203 Nox1 2.03 up 
NM_011519 Sdc1 2.18 up NM_133485 Ppp1r14c 2.03 up 
NM_009899 Clca1 2.18 up NM_008317 Hyal1 2.02 up 
XM_619639|XM_984786 Tns1 2.18 up NM_020026 B3galnt1 2.02 up 
NM_001081957 OTTMUSG000000971 2.17 up NM_175029 Atg4c 2.02 up 
 Tmem140 2.17 up NM_010789 Meis1 2.02 up 
NM_183029 Igf2bp2 2.17 up NM_031999 Gpr137b 2.01 up 
 Plxnb2 2.15 up NM_007440 Alox12 2.01 up 
NM_175155 Sash1 2.15 up NM_029499 Ms4a4c 2.01 up 
NM_023516 2310016C08Rik 2.15 up NM_008047 Fstl1 2.01 up 
NM_032400 Sucnr1 2.15 up NM_013875 Pde7b 2.01 up 
NM_144559 Fcgr4 2.15 up NM_205820 Tlr13 2.01 up 
 Tmem106a 2.14 up NM_145629 Pls3 2.01 up 
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NM_172603 Phf11 2.14 up NM_054048 Rcor2 2.00 up 
NM_026793 Myct1 2.13 up NM_021506 Sh3rf1 2.00 up 
NM_177379 Grit 2.13 up NM_175472 Zcchc11 2.00 up 
NM_013492 Clu 2.13 up NM_152803 Hpse 2.00 up 
NM_010863 Myo1b 2.12 up XM_357051|XM_908720 Gm1276 1.99 up 
NM_021460 Lipa 2.12 up NM_001081298 Lphn2 1.99 up 
NM_007945 Eps8 2.11 up NM_021334 Itgax 1.99 up 
NM_019521 Gas6 2.11 up NM_016850 Irf7 1.99 up 
NM_011303 Dhrs3 2.11 up NM_007901 Edg1 1.99 up 
NM_027102 Esam1 2.10 up NM_172742 Mtmr10 1.99 up 
NM_009254 Serpinb6a 2.10 up  H28 1.99 up 
  2.10 up NM_008057 Fzd7 1.99 up 
NM_011395 Slc22a3 2.10 up NM_175181|NM_001083810 2600010E01Rik 1.98 up 
  2.09 up NM_001025395|NM_009271 Src 1.98 up 
NM_013838 Trpc6 2.09 up NR_003508|NM_013606 Mx2 1.98 up 
NM_183201 Slfn5 2.09 up NM_031195 Msr1 1.97 up 
 Med12l 2.09 up NM_173740 Maoa 1.97 up 
NM_199146 AI451617 2.09 up NM_013690 Tek 1.97 up 
NM_146028 Stac2 2.08 up NM_010658 Mafb 1.97 up 
NM_001081160 Mdga1 2.08 up NM_207708|NM_009303 Syngr1 1.97 up 
 Sbf2 2.08 up NM_198028 Serpinb10 1.97 up 
NM_133914|NM_001039103 Rasa4 2.08 up NM_172647 F11r 1.97 up 
NM_172133 Centa2 2.07 up NM_007578 Cacna1a 1.96 up 
NM_011594 Timp2 1.94 up NM_011331 Ccl12 1.96 up 
NM_029653|NM_134062 Dapk1 1.93 up NM_177909 Slc9a9 1.96 up 
NM_008709 Mycn 1.93 up NM_010162 Ext1 1.95 up 
NM_009333 Tcf7l2 1.93 up NM_011451|NM_025367 Sphk1 1.95 up 
NM_001033126 Cd27 1.93 up NM_013730 Slamf1 1.95 up 
NM_019976 Psrc1 1.93 up NM_173006 Pon3 1.94 up 
NM_001077404 Nrp2 1.93 up NM_027326|NM_029931 Mllt3 1.94 up 
NM_018779 Pde3a 1.92 up NM_009593 Abcg1 1.94 up 
NM_023118|NM_001037905 Dab2 1.92 up NM_181071 Tanc2 1.84 up 
NM_009943 Cox6a2 1.92 up NM_009726 Atp7a 1.84 up 
NM_177644 Rasal2 1.92 up NM_030113 Arhgap10 1.84 up 
NM_020258 Slc37a2 1.92 up NM_133212 Tlr8 1.84 up 
 EG240327 1.92 up NM_181071 Tanc2 1.84 up 
NM_001004157 Scarf1 1.92 up NM_001081746 EG665378 1.84 up 
XM_973954 RP23-330D3.3 1.92 up NM_020270 Scamp5 1.84 up 
 AW112010 1.92 up NM_145226 Oas3|Oit3 1.83 up 
NM_021356 Gab1 1.92 up NM_008328 Ifi203 1.83 up 
NM_007803 Cttn 1.91 up NM_007408 Adfp 1.82 up 
NM_029023 Scpep1 1.91 up NM_008329|NM_001033450 Ifi204|Mnda 1.82 up 
NM_011361 Sgk 1.91 up NM_010575 Itga2b 1.82 up 
NM_011817 Gadd45g 1.91 up NM_008332 Ifit2 1.82 up 
NM_008148 Gp5 1.90 up NM_207217 Itfg3 1.82 up 
NM_009853 Cd68 1.90 up NM_029730 Mospd2 1.82 up 
NM_133654 Cd34 1.90 up NM_021281 Ctss 1.82 up 
NM_011708 Vwf 1.89 up NM_028248 Tmem87b 1.82 up 
NM_172777 BC057170 1.89 up NM_030601 Clca2 1.82 up 
NM_009250 Serpini1 1.89 up NM_007801 Ctsh 1.81 up 
NM_011026 P2rx4 1.89 up NM_008204 H2-M2 1.81 up 
NM_027758 Tbc1d9 1.89 up NM_025331 Gng11 1.81 up 
NM_010549|NM_010550 Il11ra1|Il11ra2 1.89 up NM_009231 Sos1 1.81 up 
NM_011173 Pros1 1.88 up NM_145516 Plekhb2 1.81 up 
NM_133211 Tlr7 1.88 up NM_009404 Tnfsf9 1.80 up 
NM_010823 Mpl 1.88 up NM_145838 St8sia6 1.80 up 
NM_011419 Jarid1d 1.88 up NM_008327|NM_011940 Ifi202b 1.80 up 
NM_172867 Zfp462 1.88 up NM_027678|NM_172642 Zranb3 1.80 up 
NM_009599 Ache 1.88 up NM_011158 Prkar2b 1.80 up 
 EG665378 1.88 up NM_007798 Ctsb 1.80 up 
NM_194464 Mrvi1 1.88 up NM_133167 Parvb 1.80 up 
 Pyhin1 1.87 up NM_029495|NM_178825 Epsti1 1.79 up 
NM_021893 Cd274 1.87 up NM_010821 Mpeg1 1.79 up 
NM_010550 Il11ra2 1.87 up  4930506M07Rik 1.79 up 
NM_021792 Iigp1 1.86 up NM_008605 Mmp12 1.79 up 
NM_010549 Il11ra1|Il11ra2 1.86 up NM_138719|NM_010313 Gnb5 1.79 up 
NM_031254 Trem2 1.86 up NM_027836|NM_001025610 Ms4a7 1.79 up 
NM_011074 Pftk1 1.86 up  AI427122 1.79 up 
NM_011866 Pde10a 1.86 up NM_030710 Slamf6 1.79 up 
NM_130449 Colec12 1.86 up NM_008624 Mras 1.79 up 
NM_008012 Akr1b8 1.85 up NM_009779 C3ar1 1.78 up 
 AW548124 1.85 up NM_133187 1110032E23Rik 1.78 up 
 Etv1 1.85 up NM_007515 Slc7a3 1.78 up 
NM_018762 Gp9 1.85 up NM_026835 Ms4a6d 1.78 up 
NM_177167 Ppm1e 1.85 up NM_175476|NM_001037727 Arhgap25 1.78 up 
NM_027356 2700038N03Rik 1.85 up NM_008357 Il15 1.78 up 
NM_001045530 Ccnjl 1.85 up NM_029068 Snx16 1.78 up 
NM_016667 Sntb1 1.85 up NM_025282 Mef2c 1.77 up 
NM_178797 Mlstd1 1.84 up NM_152804 Plk2 1.77 up 
NM_026792 Agpat5 1.84 up NM_144865 Reep2 1.77 up 
NM_026470 Spata6 1.76 up NM_011459 Serpinb8 1.77 up 
NM_144538 Rab3il1 1.76 up NM_001013366 Wdr91 1.77 up 
NM_019920 Map2k1ip1 1.76 up NM_013587 Lrpap1 1.77 up 
 AU017193 1.76 up NM_019413 Robo1 1.76 up 
NM_028270 Aldh1b1 1.76 up NM_025926|NM_027287 Dnajb4 1.76 up 
NM_008625 Mrc1 1.75 up NM_007904 Ednrb 1.76 up 
XM_205829|XM_914710 Tm4sf19 1.75 up NM_172637 Hectd2 1.76 up 
NM_021515 Ak1 1.75 up NM_013825 Ly75 1.76 up 
NM_053273 Ttyh2 1.75 up NM_024217 Cmtm3 1.69 up 
NM_009624 Adcy9 1.75 up NM_008398 Itga7 1.69 up 
NM_001003955|NM_177466 Rab11fip5 1.75 up NM_008630 Mt2 1.69 up 
NM_011360 Sgce 1.75 up NM_176073|NM_018755 Pgcp 1.69 up 
NM_011183 Psen2 1.75 up NM_027144 Arhgef12 1.69 up 
NM_011785 Akt3 1.75 up NM_153778 Atoh8 1.69 up 
NM_011197 Ptgfrn 1.75 up NM_009842 Cd151 1.69 up 
NM_019920 Map2k1ip1 1.74 up  Gm129 1.69 up 
NM_198095 Bst2 1.74 up NM_020577 As3mt 1.69 up 
NM_001039692|NM_029277 Arhgap12 1.74 up NM_011504 Stxbp3a 1.69 up 
NM_019455 Ptgds2 1.74 up NM_145501 Pi4k2a 1.69 up 
NM_027760 Rassf8 1.74 up NM_009101 Rras 1.69 up 
NM_018797 Plxnc1 1.74 up NM_008768 Orm1 1.68 up 
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 B430306N03Rik 1.74 up NM_008720 Npc1 1.68 up 
NM_029001 Elovl7 1.74 up NM_010548 Il10 1.68 up 
NM_008873 Plau 1.74 up NM_010045 Darc 1.68 up 
NM_175540 Eda2r 1.73 up NM_009808 Casp12 1.68 up 
NM_029394 Snx24 1.73 up NM_175034 Slc24a5 1.68 up 
NM_001013833|NM_011160 Prkg1 1.73 up NM_023063 Lima1 1.68 up 
NM_026013|NM_001025582 Tmem77 1.73 up NM_008102 Gch1 1.68 up 
NM_009686 Apbb2 1.73 up  Stox2 1.68 up 
NM_053180 Ccrk 1.73 up NM_028030 Rbpms2 1.68 up 
NM_007378 Abca4 1.72 up NM_133990 Il13ra1 1.67 up 
NM_172648 Ifi205 1.72 up NM_026082 Dock7 1.67 up 
NM_008876 Pld2 1.72 up NM_146073 Zdhhc14 1.67 up 
NM_028981|NM_001083616 Cacna1d 1.72 up NM_010279 Gfra1 1.67 up 
NM_139300 Mylk 1.71 up NM_010515 Igf2r 1.67 up 
NM_001005341 Ypel2 1.71 up NM_133969|NM_008455 Cyp4v3|Klkb1 1.67 up 
 Tmem65 1.71 up NM_001004363 Nuak1 1.67 up 
NM_011073 Prf1 1.71 up NM_173028 Vps13a 1.67 up 
NM_008367 Il2ra 1.71 up NM_029364 Gns 1.67 up 
NM_008443 Kif3a 1.70 up NM_080708 Bmp2k 1.67 up 
 AW555464 1.70 up NM_001033291 Usp40 1.67 up 
NM_013471 Anxa4 1.70 up NM_020578 Ehd3 1.67 up 
NM_001077364|NM_010286 Tsc22d3 1.70 up NM_010587 Itsn1 1.67 up 
NM_009465 Axl 1.70 up NM_018784 St3gal6 1.67 up 
NM_010397|NM_010399 H2-T22|H2-T9 1.70 up NM_009929 Col18a1 1.67 up 
NM_010687 Large 1.70 up NM_013835 Trove2 1.66 up 
NM_007963 Evi1 1.70 up NM_023158 Cxcl16 1.66 up 
NM_010421 Hexa 1.70 up NM_028060 Slc35f2 1.66 up 
NM_008624 Mras 1.70 up NM_009368 Tgfb3 1.66 up 
NM_001042614|NM_009155 Sepp1 1.70 up NM_144520 Sec14l2 1.66 up 
NM_172773 Slc17a5 1.70 up NM_022029 Nrgn 1.66 up 
NM_133859 Olfml3 1.70 up NM_013790|NM_176839 Abcc5 1.66 up 
NM_181542|NM_181545 Slfn10|Slfn8 1.70 up NM_173440 Nrip1 1.66 up 
NM_007837 Ddit3 1.69 up NM_138756 Slc25a36 1.66 up 
NM_010738 Ly6a 1.65 up NM_146206 Tpcn2 1.65 up 
NM_001029990 Mett11d1 1.65 up NM_172753 4732435N03Rik 1.65 up 
NM_144517 Tbc1d19 1.65 up NM_052976 Ophn1 1.65 up 
NM_011116 Pld3 1.65 up NM_025446 Aig1 1.65 up 
NM_023044 Slc15a3 1.65 up NM_011391 Slc16a7 1.61 up 
 BC013481 1.65 up NM_008608 Mmp14 1.61 up 
 Tbrg3 1.65 up NM_011150 Lgals3bp 1.61 up 
NM_008397 Itga6 1.65 up NM_010818 Cd200 1.61 up 
NM_181547 Nostrin 1.65 up NM_008121 Gja5 1.61 up 
 Phc3 1.65 up NM_080466 Kcnn3 1.61 up 
NM_033320 Glce 1.65 up NM_011584 Nr1d2 1.61 up 
NM_175512 Dhrs9 1.65 up NM_008813 Enpp1 1.61 up 
NM_183016 Cdc42bpb 1.64 up NM_199448 Fez2 1.61 up 
NM_207648 H2-Q6|H2-Q8 1.64 up NM_013683 Tap1 1.61 up 
NM_172289 Slc36a4 1.64 up NM_023386 Rtp4 1.60 up 
NM_023124 H2-Q8 1.64 up NM_010560 Il6st 1.60 up 
NM_007387 Acp2 1.64 up NM_021297 Tlr4 1.60 up 
NM_207530 Osbpl1a 1.64 up NM_013748 Clnk 1.60 up 
NM_016923 Ly96 1.64 up  8030451K01Rik 1.60 up 
XM_889589|XM_909359 EG625046 1.64 up NM_011961 Plod2 1.60 up 
NM_016769 Smad3 1.64 up NM_029898 Ankrd55 1.60 up 
NM_009707|NM_178754 Arhgap6 1.64 up  A230067G21Rik 1.60 up 
NM_001033245 Hk3 1.64 up NM_022890 Cldn12 1.60 up 
NM_026283 Samd8 1.63 up NM_028787 Slc35f5 1.60 up 
NM_175093 Trib3 1.63 up  EG665378 1.60 up 
NM_025911 Ccdc91 1.63 up NM_008533 Cd180 1.60 up 
NM_016764 Prdx4 1.63 up NM_016921 Tcirg1 1.59 up 
NM_172468 Snx30 1.63 up NM_019587 Plxnb3 1.59 up 
NM_023320 Plekho1 1.63 up NM_010819 Clec4d 1.59 up 
NM_146122 Dennd1a 1.63 up NM_001039039 Kctd21 1.59 up 
NM_008986 Ptrf 1.63 up NM_001007578 Armcx6 1.59 up 
NM_010554 Il1a 1.63 up NM_020509 Retnla 1.59 up 
NM_146126 Sord 1.63 up NM_133792 Lypla3 1.59 up 
NM_024223 Crip2 1.63 up NM_010683 Lamc1 1.59 up 
NM_172883 Mfsd7 1.63 up NM_053082 Tspan4 1.59 up 
NM_172475 Frmd4a 1.63 up NM_013839 Nr1h3 1.59 up 
 Slc44a1 1.62 up  AY223547 1.59 up 
NM_001033550 Lrrc8b 1.62 up NM_175160 Zdhhc1 1.59 up 
NM_009295 Stxbp1 1.62 up NM_173379 Leprel1 1.59 up 
NM_001025250|NM_009505 Vegfa 1.62 up NM_025332 Gtpbp8 1.58 up 
NM_013792 Naglu 1.62 up NM_013761 Srr 1.58 up 
NM_009019 Rag1 1.62 up XM_905096 Irgb10 1.58 up 
XM_001475971|XR_032907 LOC100041211 1.62 up NM_010840 Mthfr 1.58 up 
NM_023065 Ifi30 1.62 up  Cdc42bpa 1.58 up 
NM_019778 Zbtb20 1.62 up NM_010496 Id2 1.58 up 
NM_008325 Idua 1.62 up NM_009912 Ccr1 1.58 up 
NM_009655 Alcam 1.62 up NM_133891 Slc44a1 1.58 up 
NM_145530 Rhov 1.62 up NM_009052 Bex1 1.58 up 
NM_028916 Efhc2 1.62 up XM_915205|XM_985548 Syngap1 1.58 up 
NM_054040 Tulp4 1.62 up NM_028460|NM_152799 3110045G13Rik 1.58 up 
XM_001480292 LOC100048461 1.62 up NM_178772 Aadacl1 1.58 up 
NM_025449 Nicn1 1.62 up  BC031353 1.58 up 
NM_145134 Spsb4 1.62 up NM_133977 Trf 1.58 up 
NM_023409 Npc2 1.58 up XM_001479889 Cd59a 1.58 up 
NM_007715 Clock 1.58 up NM_010501 Ifit3 1.58 up 
NM_027209 Ms4a6b 1.58 up NM_013692 Klf10 1.58 up 
NM_134042 Aldh6a1 1.58 up NM_007483 Rhob 1.58 up 
NM_009706 Arhgap5 1.58 up NM_030150 Dhx58 1.58 up 
NM_011906 Gpr175 1.58 up NM_023873 Cep70 1.55 up 
NM_011347 Selp 1.58 up NM_007897 Ebf1 1.55 up 
NM_008635 Mtap7 1.57 up NM_008732 Slc11a2 1.55 up 
NM_018882 Gpr56 1.57 up NM_008007 Fgf3 1.55 up 
NM_019990 Stard10 1.57 up NM_145987 Tmem82 1.55 up 
NM_023655 Trim29 1.57 up  EG209380 1.55 up 
NM_146025 Samd14 1.57 up NM_027109 Dnase1l1 1.55 up 
NM_019734 Asah1 1.57 up NM_001009935|NM_023719 Txnip 1.55 up 
NM_028238 Rab38 1.57 up NM_008477 Ktn1 1.55 up 
NM_053090 Drctnnb1a 1.57 up NM_026674 Aph1c 1.55 up 
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NM_173370 Cds1 1.57 up NM_178119|NM_001037136 Centg2 1.55 up 
XM_001472523|XM_485967 EG434215 1.57 up XM_483890|XM_906658 Trdn 1.55 up 
NM_153103 Kif1c 1.57 up NM_011068 Pex11a 1.55 up 
NM_021414 4631427C17Rik 1.57 up NM_178667 Tfdp2 1.54 up 
NM_025760 Ptplad2 1.57 up NM_028894 Lonrf3 1.54 up 
NM_144912 Rad9b 1.57 up NM_012056 Fkbp9 1.54 up 
NM_012000 Cln8 1.57 up NM_176841 Ccdc88a 1.54 up 
NM_019580 Mir16 1.57 up NM_013750 Phlda3 1.54 up 
 EG665378 1.57 up XM_893468|XM_911460 EG628705 1.54 up 
NM_198862 Nlgn2 1.57 up NM_026719 Lmbrd1 1.54 up 
NM_172772 B230380D07Rik 1.57 up NM_007395 Acvr1b 1.54 up 
 Nlrc5 1.56 up  LOC435793 1.54 up 
NM_025359 Tspan13 1.56 up NM_145220 Appl2 1.54 up 
NM_001081347 Rhobtb1 1.56 up NM_007482 Arg1 1.54 up 
NM_172477 Dennd2a 1.56 up NM_016863 Fkbp1b 1.54 up 
NM_013489 Cd84 1.56 up NM_008737 Nrp1 1.54 up 
NM_181545 Slfn8 1.56 up NM_172708 Dok7 1.54 up 
NM_178253 Klhdc1 1.56 up NM_027340 Lipn 1.54 up 
NM_009230 Soat1 1.56 up XR_033405|XR_033767 LOC546714 1.54 up 
NM_007514|NM_001044740 Slc7a2 1.56 up NM_009452 Tnfsf4 1.54 up 
 Disp1 1.56 up NM_008161|NM_001083929 Gpx3 1.54 up 
NM_019677 Plcb1 1.56 up NM_021273 Ckb 1.54 up 
NM_139140 Spats2 1.56 up NM_010705 Lgals3 1.53 up 
XM_147850|XM_001476299 BC030046 1.56 up NM_013826 Mocs2 1.53 up 
NM_144552 Stxbp6 1.56 up NM_177178 Lmbrd2 1.53 up 
NM_008598 Mgmt 1.56 up NM_172051 Tmcc3 1.53 up 
NM_153508 Clstn3 1.56 up NM_008859 Prkcq 1.53 up 
NM_172267 Phyhd1|Lrrc8a 1.56 up NM_001037713 Fbxo39 1.53 up 
NM_011890 Sgcb 1.56 up  Cmah 1.53 up 
 Nbeal1 1.56 up NM_172893 Parp12 1.53 up 
NM_019432 Tmem37 1.56 up NM_009099 Trim30 1.53 up 
NM_009517 Zmat3 1.56 up  Zmym6 1.53 up 
NM_001045513 Raph1 1.55 up NM_001081260 Tnks1bp1 1.53 up 
NM_147220 Abca9 1.55 up NM_001001979 Megf10 1.53 up 
NM_181848 Optn 1.55 up NM_016965 Nckap1 1.53 up 
NM_175465 Sestd1 1.55 up NM_144731 Galnt7 1.53 up 
NM_011913 Best1 1.55 up NM_146001 Hip1 1.53 up 
NM_026163 Pkp2 1.55 up NM_145538 ENSMUSG00000058405 1.53 up 
NM_007426 Angpt2 1.55 up XM_981204|XM_917816 Myo9a 1.53 up 
NM_028523 Dcbld2 1.55 up  1700081L11Rik 1.53 up 
NM_178653 Sccpdh 1.55 up NM_018804 Syt11 1.53 up 
NM_028207 Dusp3 1.53 up XM_001477846 LOC672511 1.51 up 
NM_011309 S100a1 1.53 up NM_007975 F2rl3 1.51 up 
NM_011920 Abcg2 1.53 up NM_172153|NM_178142 Lcorl 1.51 up 
NM_026418 Rgs10 1.53 up NM_010395 H2-T10 1.51 up 
NM_145926 Mgat4b 1.52 up NM_008311 Htr2b 1.51 up 
NM_018819 Brp44l 1.52 up NM_010145 Ephx1 1.51 up 
NM_012048 Polk 1.52 up NM_178704 Dpy19l3 1.51 up 
NM_027154 Tmbim1 1.52 up NM_144923 Blvrb 1.51 up 
NM_013515 Stom 1.52 up NM_011505 Stxbp4 1.51 up 
 Tmem163 1.52 up NM_177386 Sfmbt2 1.51 up 
NM_025935 Tbc1d7 1.52 up NM_019832 Gkap1 1.51 up 
NM_025522 Dhrs7 1.52 up NM_027764 Rcbtb1 1.51 up 
NM_011305 Rxra 1.52 up NM_177378 Rnf150 1.51 up 
NM_010326 Gp1ba 1.52 up NM_153103 Kif1c 1.51 up 
NM_013646 Rora 1.52 up NM_029091 Klc4 1.51 up 
NM_153543 Aldh1l2 1.52 up NM_013509 Eno2 1.51 up 
NM_016780 Itgb3 1.52 up NM_177861 Tmem67 1.51 up 
NM_001079901 Repin1 1.52 up NM_011852 Oas1g 1.51 up 
NM_183355|NM_008783 Pbx1 1.52 up NM_001082553|NM_030554 Rab27b 1.51 up 
NM_016982 Vpreb1 1.52 up NM_175489|NM_001003717 Osbpl8 1.51 up 
NM_007644 Scarb2 1.52 up NM_001079824 Hnrph3 1.51 up 
NM_010171 F3 1.52 up NM_016811 Dgka 1.50 up 
XM_917816|XM_981204 Myo9a 1.52 up NM_178728 AB112350 1.50 up 
NM_009906 Tpp1 1.52 up NM_145984 Prepl 1.50 up 
 Disp1 1.52 up NM_008235 Hes1 1.50 up 
NM_010870 Naip5 1.52 up NM_026298 Ift172 1.50 up 
NM_010806 Mllt4 1.52 up NM_019581 Gtpbp2 1.50 up 
NM_177662 Ctso 1.52 up NM_018861 Slc1a4 1.50 up 
 AU023871 1.51 up NM_019578 Extl1 1.50 up 
NM_025975 Dynlt3 1.51 up NM_013529 Gfpt2 1.50 up 
NM_029655 Snx7 1.51 up NM_013784 Pign 1.50 up 
 BC022687 1.51 up NM_026316 Aldh3b1 1.50 up 
NM_027491 Rragd 1.51 up  Hrasls3 1.50 up 
NM_152895 Jarid1b 1.51 up NM_178729 Fbxl5 1.50 up 
NM_020610 Nrip3 2.21 down NM_010190 Fcnb 3.98 down 
NM_181596 Retnlg 2.20 down NM_009660 Alox15 3.97 down 
NM_178200 Hist1h2bm 2.17 down NM_001083955 Hba-a2 3.34 down 
NM_001033632 Ifitm6 2.17 down NM_010518 Igfbp5 3.33 down 
NM_011061 Padi4 2.16 down NM_008218 Hba-a1 3.26 down 
 Mrgpra2 2.15 down NM_025288 Stfa3 3.12 down 
NM_009114 S100a9 2.13 down NM_133246 Ms4a3 3.12 down 
NM_001083957|NM_009799 Car1 2.12 down NM_053111|NM_017385 Ear6|Ear7 3.11 down 
NM_145968 Tagap|Tagap1 2.11 down NM_001082546 BC100530|Stfa1 3.08 down 
NM_009382 Thy1 2.11 down NM_008220|NM_016956 Hbb-b1|Hbb-b2 3.07 down 
NM_010215 Il4i1 2.11 down NM_009127 Scd1 3.04 down 
NM_007675 Ceacam10 2.10 down NM_010720 Lipg 2.99 down 
NM_001082545 Stfa2 2.08 down NM_021274 Cxcl10 2.89 down 
NM_007695 Chi3l1 2.07 down NM_008920 Prg2 2.88 down 
NM_024444 Cyp4f18 2.07 down NM_015779 Ela2 2.84 down 
NM_017370 Hp 2.05 down NM_007894 Ear1 2.74 down 
NM_008522 Ltf 2.05 down NM_178372 Prss34 2.60 down 
NM_001042710 Prssl1 2.04 down NM_011332 Ccl17 2.58 down 
NM_019957 Dnase2b 2.04 down NM_009921 Camp 2.52 down 
NM_183370|NM_183368 Sytl3 2.03 down NM_001082545|NM_173869 Stfa2|Stfa2l1 2.51 down 
NM_023049 Asb2 2.03 down NM_013542 Gzmb 2.49 down 
NM_009712 Arsb 2.03 down NM_009846 Cd24a 2.49 down 
NM_016917 Slc40a1 2.02 down NM_153511 Il1f9 2.48 down 
NM_008501|NM_001039537 Lif 2.01 down  Mrgpra6 2.47 down 
NM_010700 Ldlr 2.00 down NM_011090|NM_011091 Pira3|Pira4|Pira11 2.46 down 
NM_008489 Lbp 1.99 down NM_009616 Adam19 2.45 down 
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NM_009132 Scin 1.99 down NM_013650 S100a8 2.45 down 
NM_026862 Cd177 1.99 down NM_011178 Prtn3 2.41 down 
NM_153546 Mboat1 1.98 down NM_007946 Epx 2.40 down 
NM_021407 Trem3 1.98 down NM_030720 Gpr84 2.37 down 
NM_031168 Il6 1.98 down NM_009402 Pglyrp1 2.37 down 
NM_139200 Pscdbp 1.98 down  BC018473 2.36 down 
NM_153101 Mrgpra2 1.97 down NM_016914 Prg3 2.34 down 
NM_009122 Satb1 1.97 down NM_009864 Cdh1 2.30 down 
NM_001004159 Clec4b2 1.96 down NM_001038604|NM_021364 Clec5a 2.30 down 
NM_013599 Mmp9 1.95 down NM_009137 Ccl22 2.29 down 
NM_207131 Cebpe 1.93 down NM_026414 Asprv1 2.26 down 
NM_175664 Hist1h2bb 1.93 down NM_031181 Siglece 2.24 down 
NM_177390 Myo1d 1.93 down NM_029796 Lrg1 2.24 down 
NM_007984 Fscn1 1.93 down NM_011269 Rhag 1.84 down 
NM_008491 Lcn2 1.93 down NM_001076679 LOC751864 1.83 down 
NM_007895|NM_017388 Ear2|Ear3 1.92 down NM_134469 Fdps 1.83 down 
NM_001013365 Osm 1.92 down NM_021283 Il4 1.83 down 
NM_001082543 Stfa1 1.91 down NM_009384 Tiam1 1.83 down 
NM_178259 Abca13 1.90 down NM_213614|NM_001001999 Sept5|Gp1bb 1.83 down 
NM_010206|NM_001079908 Fgfr1 1.90 down NM_177390 Myo1d 1.82 down 
NM_001082542 EG408196 1.90 down NM_008355 Il13 1.82 down 
NM_010482 Htr1b 1.89 down NM_011436 Sorl1 1.81 down 
NM_020034 Hist1h1b 1.89 down NM_026515 2810417H13Rik 1.81 down 
NM_010517 Igfbp4 1.89 down NM_001099217 Ly6c2 1.80 down 
NM_007895 Ear2|Ear3 1.89 down NM_022032 Perp 1.80 down 
NM_009769 Klf5 1.88 down NM_001030294 Olfm4 1.80 down 
NM_013698 Txk 1.88 down NM_009712 Arsb 1.79 down 
NM_010427 Hgf 1.87 down NM_016674 Cldn1 1.78 down 
NM_009638 Crisp1 1.87 down NM_008518 Ltb 1.78 down 
NM_010824 Mpo 1.86 down NM_053112|NM_007895 Ear10|Ear2|Ear12 1.78 down 
NM_175660 Hist1h2ab 1.85 down NM_178197 Hist1h2bh 1.78 down 
NM_172659 Slc2a6 1.66 down NM_053272 Dhcr24 1.77 down 
NM_023734 Pi16 1.66 down NM_019577 Ccl24 1.77 down 
NM_153094|NM_181064 Klrb1f 1.65 down NM_011957 Creb3l1 1.76 down 
NM_145149 Rasgrp4 1.65 down NM_172694 Megf9 1.76 down 
NM_011311 S100a4 1.65 down NM_011926|NM_001039185 Ceacam1 1.76 down 
NM_017461 Sepl1 1.64 down NM_020010 Cyp51 1.76 down 
NM_028808 P2ry13 1.64 down NM_008288|NM_001044751 Hsd11b1 1.76 down 
NM_009135 Scn7a 1.64 down  Tcrg-V2|Tcrg-V1 1.76 down 
NM_010555 Il1r2 1.64 down NM_024204 Ankrd22 1.76 down 
NM_178202|NM_178199 Hist1h2bp 1.63 down NM_001005510 Syne2 1.76 down 
NM_178202|NM_178201 Hist1h2bp 1.63 down NM_053112|NM_007895 Ear10|Ear2|Ear12 1.75 down 
NM_001033922|NM_172623 Treml4 1.63 down NM_007719 Ccr7 1.74 down 
NM_177733 E2f2 1.63 down NM_134066 Akr1c18 1.73 down 
NM_011782 Adamts5 1.62 down NM_177448 Mogat2 1.73 down 
XM_001472239 LOC433368 1.62 down NM_009477 Upp1 1.73 down 
NM_007670 Cdkn2b 1.62 down NM_023396 Rprm 1.72 down 
 Ibrdc3 1.62 down NM_030728 9930013L23Rik 1.72 down 
NM_026384 Dgat2 1.62 down NM_183249 1100001G20Rik 1.71 down 
NM_172435 P2ry10 1.62 down NM_007950 Ereg 1.71 down 
NM_025831 1300014I06Rik 1.62 down NM_011808|NM_001038642 Ets1 1.71 down 
NM_013521 Fpr1 1.62 down NM_008405 Itgb2l 1.70 down 
NM_033596 Hist2h4 1.61 down NM_007799 Ctse 1.70 down 
NM_178202|NM_178198 Hist1h2bp 1.61 down NM_175666 Hist2h2bb 1.70 down 
 Kynu 1.61 down NM_011950 Mapk13 1.70 down 
 Sprr2a 1.61 down NM_016672 Ddc 1.69 down 
NM_008230 Hdc 1.60 down NM_021406 Trem1 1.69 down 
NM_207680|NM_207681 Bcl2l11 1.60 down NM_011198 Ptgs2 1.68 down 
XR_033339 LOC100042191 1.59 down NM_010741 Ly6c1 1.68 down 
NM_020559 Alas1 1.59 down NM_178202|NM_178195 Hist1h2bp 1.68 down 
NM_001079686|NM_153399 Syne1 1.59 down NM_175535 Arhgap20 1.68 down 
NM_138648 Olr1 1.59 down NM_178202|NM_175665 Hist1h2bp 1.68 down 
 Tomm40 1.59 down XR_033108 LOC100041907 1.68 down 
 6530402F18Rik 1.58 down NM_030609 Hist1h1a 1.67 down 
NM_178183 Hist1h2ak 1.58 down NM_008812 Padi2 1.67 down 
NR_002895 Pwcr1 1.58 down NM_013596 Mc5r 1.66 down 
NR_002895 Pwcr1 1.58 down NM_010104 Edn1 1.66 down 
NR_002895 Pwcr1 1.58 down NM_153526 Insig1 1.66 down 
NR_002895 Pwcr1 1.58 down NM_016693 Map3k6 1.66 down 
NM_175652 Hist4h4 1.58 down NR_002895 Pwcr1 1.57 down 
NR_002895 Pwcr1 1.58 down NR_002895 Pwcr1 1.56 down 
NR_002895 Pwcr1 1.58 down NM_007664 Cdh2 1.56 down 
NR_002895 Pwcr1 1.57 down  Ncf1 1.56 down 
NM_172496 Cobl 1.57 down NM_019984 Tgm1 1.56 down 
NR_002895 Pwcr1 1.57 down NR_002895 Pwcr1 1.56 down 
NR_002895 Pwcr1 1.57 down NR_002895 Pwcr1 1.56 down 
 Pwcr1 1.57 down NR_002895 Pwcr1 1.56 down 
NM_201367 Gpr176 1.57 down  BC029169 1.56 down 
NM_008572 Mcpt8 1.57 down NM_013566 Itgb7 1.56 down 
NR_002895 Pwcr1 1.57 down NM_133809 Kmo 1.56 down 
NM_009104 Rrm2 1.57 down NM_007800 Ctsg 1.56 down 
 Lsm5 1.57 down NM_015736 Galnt3 1.55 down 
NM_001081302 Trio 1.57 down NM_011346 Sell 1.55 down 
NM_009811 Casp6 1.53 down NR_002895 Pwcr1 1.55 down 
NM_025436 Sc4mol 1.52 down NM_019391 Lsp1 1.55 down 
NM_001097979|NM_178202 RP23-38E20.1 1.52 down  D8Ertd82e 1.55 down 
NM_001097979|NM_178202 RP23-38E20.1 1.52 down NM_019395 Fbp1 1.55 down 
NM_145581 Siglec5 1.52 down NM_011770 Ikzf2 1.55 down 
NM_009911 Cxcr4 1.51 down NM_178165|NM_153090 Fcrl1 1.54 down 
NM_145942 Hmgcs1 1.51 down NM_139198 Plac8 1.54 down 
NM_175663 Hist1h2ba 1.51 down NM_010553 Il18rap 1.54 down 
NM_013458 Add2 1.51 down NM_008046 Fst 1.54 down 
NM_178593|NM_001038846 Rcsd1 1.51 down NM_017464 Nedd9 1.54 down 
NM_173733 Suox 1.50 down NM_007575 Ciita 1.54 down 
NM_010583 Itk 1.50 down NM_008517 Lta4h 1.53 down 
NM_026439 Ccdc80 1.50 down NM_001081445|NM_010875 Ncam1 1.53 down 
NM_024245 Kif23 1.50 down NM_010931 Uhrf1 1.53 down 
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DISCUSSION  
 
Several studies have suggested that retroviral expression of class II mutations such 
as MLL fusion genes (e.g. MLL/AF9, MLL/ENL, MLL/GAS7) or MOZ/TIF2 in the 
murine hematopoietic system is necessary but rather not sufficient to induce an acute 
myeloid leukemia (AML) that recapitulates the human disease 21,34,40,42,109. However 
until today whether secondary genetic alterations occur and what could be their 
nature remained unknown. In human AML, several small alterations such as point 
mutations (e.g. in the FLT3 or WT1 genes) can often be found in a homozygous state 
as a consequence of uniparental disomy (UPD) or loss of heterozygosity (LOH). By 
modeling the class II mutation mediated AML in a F1-hypbrid strain (FVB/N x 129/s1), 
we aimed to identify LOH of loci that could carry functionally collaborating mutated 
oncogenes or tumor suppressor genes. However, our genome-wide haplotype 
analysis using microsatellite marker based genotyping and SNP arrays did not reveal 
any large regions of LOH in 21 mouse leukemias induced by MLL/ENL or MOZ/TIF2. 
It is highly likely that the resolution of our technology with only about 1500 
polymorphic markers throughout the 19 murine chromosomes was too low. 
Nevertheless, at the time of the analysis there was no commercial platform available 
that would have allowed increasing the sensitivity of our analysis. New technologies 
like high-throughput parallel sequencing will allow screening the whole genome of a 
leukemic cell for genetic lesions such as fusion genes, small mutations as well as 
epigenetic modification in a single analysis 110,111. Using this technology, Ley and co-
workers recently characterized an acute myeloid leukaemia genome of an AML 
patient that showed no gross chromosomal alterations in normal karyotyping. 
Strikingly, mutations in only 8 genes were found: 1 was the recurrent FLT3-ITD 
mutation combined with single mutations in 7 genes with unknown biological 
consequence, however, none of these 7 mutations were found in 100 unrelated AML 
patients 112. 
 
Recent studies have shown that the retroviral insertion mutagenesis of replication 
defective retrovirus may be sufficient to immortalize hematopoietic progenitors and 
could favor the driver mutations in oncogenic transformation 79,80. In our experiment, 
we used the replication-defective Murine Stem Cell Virus (MSCV) to express the 
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class II mutations (MLL/ENL or MOZ/TIF2) together with an internal ribosomal entry 
site (IRES)-regulated EGFP marker 79. Thus, the integration of retrovirus could 
theoretically also act as the key cooperating event in these mouse leukemia models. 
Using a PCR based retroviral integration cloning strategy, we were able to clone 42 
integrations with 66 integration flanking genes in 2 murine leukemia models. It has 
been previously shown that oncogenic genes identified by retroviral insertion 
mutagenesis are more frequently differentially expressed in human acute leukemia 
than randomly selected genes or genes located more distantly from provirus 
integration 85,113. Interestingly, some genes flanking the integration sites such as 
SOCS1, JARID2, PTPRE, HSP90, GADD45, MGAT5, PP2R5C, LHX2 or MN1 have 
been previously linked to carcinogenesis 114-120. 
 
The suppressor of cytokine signaling (SOCS)-1, a negative regulator of the Janus 
family tyrosine kinases (JAKs), has been reported to be hypermethylated in its 
promoter region in the majority of primary AML cases studied, which led to 
decreased expression and may contributed to malignant transformation 117. HSP90 
(heat-shock 90-kd protein 1, alpha) is a molecular chaperone that plays a key role in 
the conformational maturation of oncogenic signaling proteins, including 
HER2/ERBB2, AKT, RAF1, BCR/ABL, and mutated p53. In tumor cells, HSP90 
complexes keep in an activated, high-affinity conformation that facilitates malignant 
progression 114. High levels of LHX2 (LIM-homeobox gene) expression are frequently 
observed in CML patients, regardless of disease status. LHX2 is located in the same 
region as the reciprocal translocation that generates the BCR/ABL chimera, and it is 
silenced in normal bone marrow due to DNA methylation. However, in CML cells both 
alleles of LHX2 locus were heavily hypomethylated, suggesting that the 
transcriptional activation of LHX2 in CML likely results from a cis-acting effect, rather 
than a trans-acting effect of the BCR/ABL fusion protein 121. In the mouse model, the 
expression of Lhx2 in murine bone marrow led to immortalized hematopoietic cells 
with multipotent differentiation potential, and transplantation of these cells in 
irradiated recipients caused a chronic myeloproliferative disorder 115,116. 
 
The integration near the Mn1 locus resulted in significantly increased levels of mRNA 
expression of Mn1 in the MLL/ENL expressing leukemic blasts. As these blasts 
carried several integrations, the integration targeting Mn1 was clonally selected as 
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shown by PCR analysis of single clones grown in methylcellulose (Fig. 3). The Mn1 
gene locus has been previously reported as the recurrent integration site in mouse 
models of human hematological malignancies induced by retroviral oncogene 
expression such as NUP98/HOXD13 fusion or mutated AML1 106,107. Several recent 
studies suggested functional links between MLL, CBF and EVI1. EVI1 seems to be a 
downstream target of MLL/ENL and NUP98/HOX mediated transformation 122-125. In 
addition, direct interactions between MLL and AML1 seem to provide epigenetic 
regulation of gene expression in leukemic cells 126. Although the exact molecular 
mechanisms remain to be elucidated, a positive role of MN1 in a putative pathway 
involving CBF and EVI1 blocking differentiation and providing aberrant self-renewal 
could explain why a clone with the proviral integration mediated elevated MN1 
expression would be selected in presence of the MLL/ENL fusion. 
 
As MN1 showed in vitro and in vivo leukemogenic potential (Fig. 3)100,101, retroviral 
integration-mediated MN1 overexpression in MLL/ENL induced leukemia suggested 
functional cooperation. Indeed, co-expression of MN1 with MLL/ENL resulted in the 
induction of an aggressive AML-like phenotype after a significantly reduced latency 
period compared to MLL/ENL or MN1 alone (Fig. 4). Previous studies have proposed 
that in addition to hematopoietic stem cells (HSCs), committed progenitor cells such 
as common myeloid or lymphoid progenitors (CMPs, CLPs) or even granulocyte-
macrophage progenitors (GMPs) can also be targets of MLL/ENL, MLL/AF9, 
MLL/AF4 or MOZ/TIF2 induced transformation 21,41,108.  Interestingly, in normal mice 
the highest levels of MN1 were found in GMPs 100. Detailed comparison of the 
MLL/ENL induced leukemia with the disease induced by expression of MLL/ENL and 
MN1 suggests that co-expression could lead to an expansion of the GMP population. 
Increased clonogenic activity of these cells further suggests that MN1 also regulates 
genes implicated in self-renewal. Accelerated induction of a leukemic phenotype in 
secondary transplants further supports the idea that GMPs represent a prominent 
disease initiating cell pool (also often referred as leukemia stem cells) in 
MLL/ENL+MN1 leukemia. Indeed, reconstitution of sorted GMP cells from MLL/ENL 
and MLL/ENL+MN1 leukemias into secondary recipients fully supported this idea 
(Fig. 5D). Further studies are needed to determine whether elevated MN1 levels 
would also increase the pool of leukemia-initiating cells in leukemias harboring other 
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MLL fusions, or other alterations previously linked to elevated MN1 levels like inv16, 
and alterations of EVI1 that are often associated with MN1 overexpression 99,100. 
 
In adult de novo AML without detectable cytogenetic abnormalities, MN1 
overexpression was associated with poor response to therapy, a higher disease 
relapse rate and shorter overall survival 102. These clinical observations as well as 
our experimental work suggest that elevated MN1 expression might be a general 
signature for an expanded leukemic stem cell population. However, the nature of the 
disease-initiating stem cell in MLL fusion genes induced murine leukemia is still a 
matter of debate: both, expression of Gr1/Mac1+ and c-Kit+ covering 25% of the 
blasts, as well as lineage-negative (less than 1% of leukemic blasts) Leukemic-HSCs, 
L-GMPs, L-CLPs have been proposed to act as leukemia stem cells 21,34,42,108. 
Nonetheless, independently of the chosen phenotypic markers, we observed a 
significant increase in potential leukemic stem cell pool when MN1 was co-expressed 
with MLL/ENL as illustrated by secondary transplantation experiments (Fig. 5).  
 
Our results suggest functional cooperation of MN1 with MLL fusions in 
leukemogenesis. However, not all studied MLL fusion positive human leukemia cell 
lines expressed elevated MN1 levels (Fig. 9A). In addition, our own and other’s gene 
expression profiling studies of experimental models of MLL leukemias never revealed 
MN1 as being a primary up-regulated target (unpublished observation) 42,108. These 
observations raised the possibility that the MN1 expression status in a leukemic blast 
might be dependent on the maturation grade of the cell that was initially targeted by 
the MLL fusion and/or on a currently unknown mechanism that would maintain the 
MN1 levels high. Interestingly, an unusual methylation pattern of the MN1 promoter 
region was recently reported in leukemic cells, suggesting that epigenetic 
mechanisms might be needed to sustain the elevated MN1 expression levels in cell 
transformed by oncogenes such as MLL fusions 127. 
 
It has been demonstrated that MN1 primarily acts as transcriptional co-regulator 93. 
Transient overexpression of MN1 is associated with significant changes in the gene 
expression programs involving a large number of genes as shown recently in a 
human leukemia cell line (U937) 128. In our model, overexpression of MN1 in primary 
bone marrow cells resulted in up-regulation of a set of genes that have been 
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associated with normal and malignant hematopoiesis (Fig. 6, Table 6). Moreover, 
some of these genes like FLT3, CD34, DLK1, MEIS1, and HLF were also up-
regulated in blasts from murine leukemias induced by MN1 or MLL/ENL + MN1 
expression. These MN1 regulated genes such as FLT3 are well known to be up-
regulated and functionally involved in various human and mouse leukemias mediated 
by different fusion genes. Expression levels of FLT3 have a negative prognostic 
impact on MLL fusion positive pediatric leukemias and FLT3 has been validated as a 
potential therapeutic target 129-131. Interestingly, FLT3, DLK1 and HLF seem to be 
deregulated upon aberrant MEIS1 or HOXA activity, but we did not found any HOXA 
gene that were up-regulated upon transient MN1 overexpression. Nevertheless, 
blasts from leukemias induced by MN1 or MLL/ENL + MN1 expressed significantly 
elevated levels of several genes of the HOXA cluster (HOXA5, HOXA7, HOXA9 and 
HOXA10) suggesting a regulation through additional genetic hits (data not shown). 
 
Strikingly, transient and stable expression of MN1 was always associated with 
increased CD34 expression (FIG. 6). Although the surface glycophosphoprotein 
CD34 is widely used as marker for early lympho-hematopoietic stem and progenitor 
cells, its biologic function remains not well understood 132. Impaired clonogenic 
growth of MN1 transformed progenitor cells by CD34 siRNA mediated knockdown 
(Fig. 7C & D) suggests that CD34 could play an active role in MN1 mediated 
transformation. Moreover, a significant correlation of MN1 expression with CD34 
levels was not only seen in the mouse leukemia model but also in cases of B-cell 
ALL or infant leukemias as a small cohort of primary pediatric leukemias (Fig. 7). 
These observations are currently being validated in a larger cohort of pediatric acute 
leukemia patients. 
 
By exploring the role of MN1 in pediatric leukemia, we found significantly elevated 
levels of MN1 mRNA in a large fraction of B-cell ALL and infant leukemia cases (Fig. 
8). Previous studies in adult AML have demonstrated deregulated expression of MN1 
being associated with either alteration of 3q26 (EVI1) or inv16 (CBF?) 99,100. In adult 
AML with normal cytogenetics, increased levels of MN1 were proposed to be a 
negative prognostic factor 102. In our pediatric cohort of leukemia patients, increased 
MN1 expression was often associated with the presence of MLL fusions. However, 
the group of patients with normal cytogenetics and elevated MN1 levels was too 
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small in our cohort to draw any conclusion about MN1 as a sole prognostic biomarker 
in pediatric leukemia. 
 
In contrast to adults, most cases of pediatric leukemia with significantly elevated MN1 
levels are of B-cell origin independently of whether or not they were carrying an MLL 
fusion. In mouse models, expression of MN1 always resulted in the generation of 
myeloid disorders 100,101. Further work will be necessary to clarify this discrepancy. 
Nevertheless, we were able to find increased expression of MN1 target genes (CD34, 
FLT3) not only in the murine system, but also in most human cases with elevated 
MN1 (Figs. 6D & 7A).  
 
Forced siRNA-mediated down-regulation of MN1 expression in cells that overexpress 
MN1 impaired growth in methylcellulose (colony formation) as well as in liquid culture. 
MN1 knockdown was associated with cell cycle arrest in G0/G1 phase (Fig. 9). These 
results showed, for the first time, that aberrant MN1 expression could be an important 
factor for proliferation of leukemic cells. Although early cell loss upon antibiotic 
selection cannot be excluded in our experiments, we did not observe any significant 
apoptotic cell death or signs of cellular senescence upon MN1 knockdown (data not 
shown). As leukemic and normal hematopoietic cells expressing low levels of MN1 
were not affected by siRNA-mediated knockdown, selective inhibition of MN1 in 
leukemia initiating cells might be possible without affecting normal tissue. Future 
structure-function studies might be able to provide essential clues for therapeutic 
targeting of the aberrant MN1 activity found in a significant portion of pediatric acute 
leukemia patients. 
 
The observations from my PhD work suggest that MN1 is a functional collaborator to 
MLL/ENL (and probably also other leukemogenic class II mutations) by increasing 
the compartment of leukemic stem cells through a distinct genetic program. 
Furthermore, I have identified some potential downstream target genes of MN1 that 
might be executors of its pro-leukemic activity. Although we are just at the beginning 
of understanding the role of MN1 in normal and malignant hematopoiesis, my work 
showed for the first time that elevated MN1 levels support proliferation of human 
acute leukemia cells suggesting that targeting aberrant MN1 activity could open new 
therapeutic avenues.  
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PERSPECTIVE  
 
In our cohort of pediatric leukemia patients, we unexpectedly found significantly 
elevated MN1 expression levels in immature B-cell ALL and infant leukemias. As 
MN1 has never been studied in the B-cell lineage, the role of MN1 in the normal and 
malignant B-cells remains to be elucidated. The currently used bone marrow 
transduction & transplantation model of murine leukemia introduces a bias for 
developing myeloid malignancies due to the culture conditions (IL-3, IL-6 and mSCF) 
used to stimulate growth of the cells for efficient transduciton. In order to address the 
consequence of elevated MN1 levels in lymphoid cells, we therefore plan to 
transduce enriched lymphoid progenitors with the MN1 retrovirus in the medium that 
favors lymphoid cell growth (containing IL-7, FL and IL-11) before transplantation. 
These experiments could shed more light on the role of MN1 in lymphoblastic 
leukemia.  
 
In addition, we will also determine the MN1 expression in normal B-cell precursors 
ranging from CLPs to pre-B, pro-B and mature B cells. Regulated MN1 expression 
during B-cell differentiation would suggest that this gene might play a role in normal 
B-cell development. Moreover, conditional ablation of MN1 expression in the 
lymphoid lineage would provide a perfect system to explore MN1 in normal and 
malignant B-cells. There are several laboratories currently aiming to develop 
conditional MN1 knockout animals. 
 
To further study the role of MN1 in B-cell ALL, we are currently determining MN1 
expression levels in a larger panel of human ALL cell lines. Following the same 
strategy used for AML cells, we will use lentivirally expressed siRNAs to analyze the 
effects of MN1 knockdown on growth and survival of these cells (Fig. 9). We have 
also cloned the full-length MN1 cDNA in lentivirus to overexpress MN1 in cells with 
low or undetectable levels of expression of endogenous MN1. Subsequent gene 
expression profiling studies in B-ALL cells upon MN1 knockdown or overexpression 
should provide more information about the role of this oncogene in B-cell leukemia. 
The extracted putative MN1 target genes will be further validated in a large panel of 
B-cell ALL patient samples.    
 80 
Several reports have recently suggested that MN1 might act as a transcriptional co-
activator although it may not bind DNA directly. The so far most investigated 
substrate supporting this hypothesis is that a complex formed by MN1 and the co-
activators p300 or RAC3 that synergistically activated retinoic-acid receptor 
(RAR/RXR) regulated transcription 94,133. In addition, MN1 also indirectly interacted 
with the vitamin D receptor via currently unknown co-activators 134. However, how 
does MN1 exert its oncogenic transforming potential in hematopoietic cells remains 
unclear. Although the gene expression profiling results of ours (Fig. 6, Table 6) and 
others 128,135 revealed some transcriptional factors that were regulated by transient 
expression of MN1, the underlying mechanisms remain to be identified. A protein-
protein interaction screen would illustrate the potential transcription factors or co-
activators that might physically interact with MN1, and further experiments such as 
chomatin-immunoprecipitation analysis could provide important insights about which 
genes are responsible for the self-renewal and proliferation of hematopoietic cells 
regulated by MN1. A previous study has suggested that the very N-terminal region of 
MN1 is important for its transactivation activity, however, a detailed structure-function 
analysis of MN1 is missing 94. Therefore, we have started to clone and express a 
series of N- and C-terminal MN1 deletion mutants (Fig. 10). Preliminary results 
indicated that the N-terminal region of MN1 seems to be critical for its transforming 
activity. Further functional characterization of MN1 should elucidate the molecular 
mechanisms underlying its oncogenic potential, and facilitate future therapeutic 
targeting of the aberrant MN1 activity in leukemia patients. 
 
 
 
 
Fig. 10. In vitro transforming activity of MN1 deletion mutants 
The C-terminal (A) and N-terminal (B) MN1 deletion mutants were generated as depicted 
and cloned into MSCV-IRES-GFP vector. CR stands for C-terminal and N stands for N-
terminal MN1 deletion mutants, and the size of deletion mutants is indicated. The expression 
of HA-tagged MN1 deletion mutants in 293T cells was detected by Westernblot analysis 
using anti-HA antibody. The murine bone marrow cells were transduced with MSCV 
retrovirus expressing different MN1 deletion mutants, and then replated in methylcellulose up 
to 4 rounds. 
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